<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01578850</url>
  </required_header>
  <id_info>
    <org_study_id>B1801315</org_study_id>
    <secondary_id>2011-005448-87</secondary_id>
    <secondary_id>B1801315</secondary_id>
    <nct_id>NCT01578850</nct_id>
  </id_info>
  <brief_title>Study Conducted in Subjects With Rheumatoid Arthritis Who Have Moderate to Severe Disease Activity Despite Methotrexate Therapy With or Without Other Non Biologic Disease Modifying Antirheumatic Drugs (DMARDs)for at Least 12 Weeks Prior to Screening</brief_title>
  <official_title>A Randomized, Double-blind Placebo-controlled Study Of The Maintenance Of Efficacy Of Etanercept Plus Dmard(s) Compared With Dmard(s) Alone In Subjects With Rheumatoid Arthritis After Achieving An Adequate Response With Etanercept Plus Dmard(s)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare the maintenance of efficacy of the combination of etanercept 50 mg once weekly
      plus methotrexate with or without other disease modifying antirheumatic drugs therapy with
      that of methotrexate with or without other disease modifying antirheumatic drugs therapy at
      Week 52 in subjects with moderately to severely active rheumatoid arthritis who have achieved
      low disease activity after 24 weeks of therapy with open label etanercept 50 mg once weekly
      plus MTX with or without other disease modifying antirheumatic drugs therapy.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2012</start_date>
  <completion_date type="Actual">March 2015</completion_date>
  <primary_completion_date type="Actual">March 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants Who Remained in Low Disease Activity (LDA) (Disease Activity Score in 28 Joints-erythrocyte Sedimentation Rate [DAS28-ESR] &lt;3.2) at Week 52.</measure>
    <time_frame>Baseline and Week 52</time_frame>
    <description>Proportion of participants who remained in LDA DAS28-ESR &lt;3.2 at Week 52 is presented below.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Remained in Remission at Week 52 (DAS28-ESR)</measure>
    <time_frame>Baseline and Week 52</time_frame>
    <description>Proportion of participants who remained in Remission (DAS28-ESR &lt;2.6) at Week 52.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving LDA (DAS28-ESR and DAS28-C-reactive Protein [CRP]) at Each Visit During Period 1</measure>
    <time_frame>Baseline, Weeks 4, 8, 16 and 24</time_frame>
    <description>Proportion of participants who achieved LDA (DAS28-ESR and DAS28-CRP at each visit during period 1 is presented below.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving LDA (DAS28-ESR and DAS28-CRP) at Each Visit During Period 2</measure>
    <time_frame>Baseline, Weeks 24, 28, 36, 44 and 52</time_frame>
    <description>Proportion of participants who achieved LDA (DAS28-ESR and DAS28-CRP at each visit during period 2 is presented below.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving Remission (DAS28-ESR and DAS28-CRP) at Each Visit During Period 1</measure>
    <time_frame>Baseline, Weeks 4, 8, 16 and 24</time_frame>
    <description>Proportion of participants who achieved remission (DAS28-ESR and DAS28-CRP at each visit during period 1 is presented below.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving Remission (DAS28-ESR and DAS28-CRP) at Each Visit During Period 2</measure>
    <time_frame>Baseline, Weeks 24, 28, 36, 44 and 52</time_frame>
    <description>Proportion of participants who achieved LDA (DAS28-ESR and DAS28-CRP at each visit during period 2 is presented below.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in DAS28-CRP and DAS28-ESR in Period 1</measure>
    <time_frame>Baseline, Weeks 4, 8, 16 and 24</time_frame>
    <description>The DAS assessment is a derived measurement with differential weight given to each component. The DAS28-ESR and DAS28-CRP was calculated at every visit within the clinical database in period 1. The components of the DAS28 ESR score assessment are: Tender/ Painful Joint Count (28), Swollen Joint Count (28); ESR, Subject General Health VAS assessment. The components of the DAS28 CRP score assessment were: Tender/Painful Joint Count (28); Swollen Joint Count (28), hsCRP, and the Subject General Health VAS assessment. This efficacy measurement was made at every study visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in DAS28-CRP and DAS28-ESR in Period 2</measure>
    <time_frame>Baseline, Weeks 24, 28, 36, 44 and 52</time_frame>
    <description>The DAS assessment is a derived measurement with differential weight given to each component. The DAS28-ESR and DAS28-CRP was calculated at every visit within the clinical database in period 2. The components of the DAS28 ESR score assessment are: Tender/ Painful Joint Count (28), Swollen Joint Count (28); ESR, Subject General Health VAS assessment. The components of the DAS28 CRP score assessment were: Tender/Painful Joint Count (28); Swollen Joint Count (28), hsCRP, and the Subject General Health VAS assessment. This efficacy measurement was made at every study visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Had a Recurrence of Disease Symptoms During Period 2, Based on the Protocol Criteria</measure>
    <time_frame>Baseline and Week 52</time_frame>
    <description>Flare is defined as the criteria of loss of LDA plus ≥0.6 unit worsening in DAS28-ESR score during period 2.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving European League Against Rheumatism (EULAR) Good and or Moderate Responses (by Both DAS28-ESR and DAS28-CRP Scores) at Each Visit During Period 1.</measure>
    <time_frame>Baseline, Weeks 4, 8, 16 and 24</time_frame>
    <description>EULAR response is based on DAS28-ESR scores. The following good and moderate response is defined based on DAS28-ESR at endpoint (DAS28-ESR improvement at from Baseline in parenthesis): ≤3.2 units (&gt;1.2 units) is good response; ≤3.2 units (0.6-1.2 units) are moderate response; ≤3.2 units (≤0.6 units) are no response.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving EULAR Good and or Moderate Responses (by Both DAS28-ESR and DAS28-CRP Scores) at Each Visit During Period 2.</measure>
    <time_frame>Baseline, Weeks 24, 28, 36, 44 and 52</time_frame>
    <description>EULAR response is based on DAS28-ESR scores. The following good and moderate response is defined based on DAS28-ESR at endpoint (DAS28-ESR improvement at from Baseline in parenthesis): ≤3.2 units (&gt;1.2 units) is good response; ≤3.2 units (0.6-1.2 units) are moderate response; ≤3.2 units (≤0.6 units) are no response.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving LDA or Remission Based on Clinical Disease Activity Index (CDAI) and Simplified Disease Activity Index (SDAI) at Each Visit During Period 1.</measure>
    <time_frame>Baseline, Weeks 4, 8, 16 and 24</time_frame>
    <description>SDAI and CDAI are defined as:
1) SDAI = DAS28 prorated Swollen Joint Count (0-28) + DAS28 prorated Tender Joint Count (0-28) + Physician Global Assessment of arthritis (0-10) + Subject Global Assessment of arthritis (0-10) + hs CRP (in mg/dL) in Period 1. 2) CDAI = DAS28 prorated Swollen Joint Count (0-28) + DAS28 prorated Tender Joint Count (0 28) + Physician Global Assessment of arthritis (0-10) + Subject Global Assessment of arthritis (0-10) in Period 1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving LDA or Remission Based on CDAI and SDAI at Each Visit During Period 2.</measure>
    <time_frame>Baseline, Weeks 24, 28, 36, 44 and 52</time_frame>
    <description>SDAI and CDAI are defined as:
1) SDAI = DAS28 prorated Swollen Joint Count (0-28) + DAS28 prorated Tender Joint Count (0-28) + Physician Global Assessment of arthritis (0-10) + Subject Global Assessment of arthritis (0-10) + hs CRP (in mg/dL) in Period 2. 2) CDAI = DAS28 prorated Swollen Joint Count (0-28) + DAS28 prorated Tender Joint Count (0 28) + Physician Global Assessment of arthritis (0-10) + Subject Global Assessment of arthritis (0-10) in Period 2.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of CDAI and SDAI at Each Visit During Period 1.</measure>
    <time_frame>Baseline, Weeks 4, 8, 16 and 24</time_frame>
    <description>SDAI and CDAI are defined as:
1) SDAI = DAS28 prorated Swollen Joint Count (0-28) + DAS28 prorated Tender Joint Count (0-28) + Physician Global Assessment of arthritis (0-10) + Subject Global Assessment of arthritis (0-10) + hs CRP (in mg/dL) in Period 1. 2) CDAI = DAS28 prorated Swollen Joint Count (0-28) + DAS28 prorated Tender Joint Count (0 28) + Physician Global Assessment of arthritis (0-10) + Subject Global Assessment of arthritis (0-10) in Period 1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of CDAI and SDAI at Each Visit During Period 2</measure>
    <time_frame>Baseline, Weeks 24, 28, 36, 44 and 52</time_frame>
    <description>SDAI and CDAI are defined as:
1) SDAI = DAS28 prorated Swollen Joint Count (0-28) + DAS28 prorated Tender Joint Count (0-28) + Physician Global Assessment of arthritis (0-10) + Subject Global Assessment of arthritis (0-10) + hs CRP (in mg/dL) in Period 2. 2) CDAI = DAS28 prorated Swollen Joint Count (0-28) + DAS28 prorated Tender Joint Count (0 28) + Physician Global Assessment of arthritis (0-10) + Subject Global Assessment of arthritis (0-10) in Period 2.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving American College of Rheumatology (ACR) ACR20, ACR50, ACR70 and ACR90 (by 66/68 Joint Counts) During Period 1 at Each Visit.</measure>
    <time_frame>Baseline, Weeks 4, 8, 16 and 24</time_frame>
    <description>A 66 swollen and 68 tender joint count was used for calculating ACR responses. The ACR's definition for calculating improvement in RA (ACR20) was calculated as a 20% improvement in tender and swollen joint counts and 20% improvement in 3 of the 5 remaining ACR core set measures: subject and physician global assessments of arthritis, pain, disability, and an acute phase reactant. Similarly, ACR50, ACR70 and ACR90 were calculated with the respective percent improvement. This efficacy measurement was made at every study visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving ACR20, ACR50, ACR70 and ACR90 (by 66/68 Joint Counts) During Period 2 at Each Visit.</measure>
    <time_frame>Baseline, Weeks 24, 28, 36, 44 and 52</time_frame>
    <description>A 66 swollen and 68 tender joint count was used for calculating ACR responses. The ACR's definition for calculating improvement in RA (ACR20) was calculated as a 20% improvement in tender and swollen joint counts and 20% improvement in 3 of the 5 remaining ACR core set measures: subject and physician global assessments of arthritis, pain, disability, and an acute phase reactant. Similarly, ACR50, ACR70 and ACR90 were calculated with the respective percent improvement. This efficacy measurement was made at every study visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the Tender and Swollen Joint Counts at Each Visit During Period 1 (Using 28 Joint Count as Well as 66/68 Joint Counts).</measure>
    <time_frame>Baseline, Weeks 4, 8, 16 and 24</time_frame>
    <description>A total of 66 swollen and 68 tender joints were assessed for tenderness/pain and swelling by the same qualified personnel (when possible) at each visit. For ACR responses, a 66/68 joint count was used. For DAS28-ESR, Simplified Disease Activity Index (SDAI), and Clinical Disease Activity Index (CDAI) calculations, the 28 joint count was used, which included: shoulders, elbows, wrists, metacarpophalangeal (MCP) joints, proximal interphalangeal (PIP) joints, and knees.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the Tender and Swollen Joint Counts at Each Visit During Period 2 (Using 28 Joint Count as Well as 66/68 Joint Counts).</measure>
    <time_frame>Baseline, Weeks 24, 28, 36, 44 and 52</time_frame>
    <description>A total of 66 swollen and 68 tender joints were assessed for tenderness/pain and swelling by the same qualified personnel (when possible) at each visit. For ACR responses, a 66/68 joint count was used. For DAS28-ESR, Simplified Disease Activity Index (SDAI), and Clinical Disease Activity Index (CDAI) calculations, the 28 joint count was used, which included: shoulders, elbows, wrists, metacarpophalangeal (MCP) joints, proximal interphalangeal (PIP) joints, and knees.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the Physician Global Assessment of Arthritis at Each Visit During Period 1</measure>
    <time_frame>Baseline, Weeks 4, 8, 16 and 24</time_frame>
    <description>The investigator estimated the subject's overall disease activity over the last 2 to 3 days (independent of the Subject Global Assessment of arthritis) using a scale between 0 (no disease activity) and 10 (extreme disease activity) and marking one number with an 'X'.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the Physician Global Assessment of Arthritis at Each Visit During Period 2</measure>
    <time_frame>Baseline, Weeks 24, 28, 36, 44 and 52</time_frame>
    <description>The investigator estimated the subject's overall disease activity over the last 2 to 3 days (independent of the Subject Global Assessment of arthritis) using a scale between 0 (no disease activity) and 10 (extreme disease activity) and marking one number with an 'X'.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the Subject Global Assessment of Arthritis in Period 1</measure>
    <time_frame>Baseline, Weeks 4, 8, 16 and 24</time_frame>
    <description>Subjects assessed their overall disease activity over the last 2 to 3 days using a scale between 0 (no disease activity) and 10 (extreme disease activity), which corresponded to the magnitude of their pain) and marked one number with an 'X'.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the Subject Global Assessment of Arthritis in Period 2</measure>
    <time_frame>Baseline, Weeks 24, 28, 36, 44 and 52</time_frame>
    <description>Subjects assessed their overall disease activity over the last 2 to 3 days using a scale between 0 (no disease activity) and 10 (extreme disease activity), which corresponded to the magnitude of their pain) and marked one number with an 'X'.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Morning Stiffness (Measured in Minutes) at Each Visit During Period 1</measure>
    <time_frame>Baseline, Weeks 4, 8, 16 and 24</time_frame>
    <description>Morning stiffness was defined as stiffness in and around the joints, lasting at least 1 hour before maximal improvement. Participants assessed their overall disease activity over the last 2 to 3 days using a scale between 0 (no disease activity) and 10 (extreme disease activity), which corresponded to the magnitude of their pain) and marked one number with an 'X'.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Morning Stiffness (Measured in Minutes) at Each Visit During Period 2</measure>
    <time_frame>Baseline, Weeks 24, 28, 36, 44 and 52</time_frame>
    <description>Morning stiffness was defined as stiffness in and around the joints, lasting at least 1 hour before maximal improvement. Participants assessed their overall disease activity over the last 2 to 3 days using a scale between 0 (no disease activity) and 10 (extreme disease activity), which corresponded to the magnitude of their pain) and marked one number with an 'X'.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the Subject General Health Visual Analog Scale (VAS) and Pain VAS at Each Visit During Period 1</measure>
    <time_frame>Baseline, Weeks 4, 8, 16 and 24</time_frame>
    <description>Participants were asked to answer the question &quot;In general how would you rate your health over the last 2 3 weeks?&quot; by marking a vertical line at the appropriate position through the 100 mm VAS. The length on the line was measured from the left (in mm). For Pain VAS, participants assessed the severity of their arthritis pain during the last 2 to 3 days using a 100 mm VAS by marking a vertical line at the appropriate position on the scale between 0 (no pain) and 100 (most severe pain), which corresponded to the magnitude of their pain.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the Subject General Health VAS and Pain VAS at Each Visit During Period 2</measure>
    <time_frame>Baseline, Weeks 24, 28, 36, 44 and 52</time_frame>
    <description>Participants were asked to answer the question &quot;In general how would you rate your health over the last 2-3 weeks?&quot; by marking a vertical line at the appropriate position through the 100 mm VAS. The length on the line was measured from the left (in mm). For Pain VAS, participants assessed the severity of their arthritis pain during the last 2 to 3 days using a 100 mm VAS by marking a vertical line at the appropriate position on the scale between 0 (no pain) and 100 (most severe pain), which corresponded to the magnitude of their pain.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in CRP and ESR at Each Visit During Period 1</measure>
    <time_frame>Baseline, Weeks 4, 8, 16 and 24</time_frame>
    <description>The DAS assessment is a derived measurement with differential weight given to each component. The DAS28-ESR and DAS28-CRP was calculated at every visit within the clinical database in period 1. The components of the DAS28 ESR score assessment are: Tender/ Painful Joint Count (28), Swollen Joint Count (28); ESR, Subject General Health VAS assessment. The components of the DAS28 CRP score assessment were: Tender/Painful Joint Count (28); Swollen Joint Count (28), hsCRP, and the Subject General Health VAS assessment. This efficacy measurement was made at every study visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in CRP and ESR at Each Visit During Period 2</measure>
    <time_frame>Baseline, Weeks 24, 28, 36, 44 and 52</time_frame>
    <description>The DAS assessment is a derived measurement with differential weight given to each component. The DAS28-ESR and DAS28-CRP was calculated at every visit within the clinical database in period 1. The components of the DAS28 ESR score assessment are: Tender/ Painful Joint Count (28), Swollen Joint Count (28); ESR, Subject General Health VAS assessment. The components of the DAS28 CRP score assessment were: Tender/Painful Joint Count (28); Swollen Joint Count (28), hsCRP, and the Subject General Health VAS assessment. This efficacy measurement was made at every study visit.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">491</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etanercept</intervention_name>
    <description>etanercept 50mg once weekly + methotrexate with or without other DMARDs</description>
    <arm_group_label>Group A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>etanercept placebo once weekly + methotrexate with or without other DMARDs</description>
    <arm_group_label>Group B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subject has a minimum 1 year history/diagnosis of rheumatoid arthritis based on the
             1987 American College of Rheumatology (ACR) Revised criteria for RA.

          2. Subject must have active rheumatoid arthritis despite methotrexate (MTX) therapy of
             ≥10 mg/wk for at least 12 weeks. The MTX dose must be stable for at least 4 weeks
             immediately prior to screening.

        Exclusion Criteria:

          1. Subjects who used any of the following systemic treatments during the washout periods
             given below:

               1. Oral corticosteroid dose of prednisone &gt;7.5 mg/day (or equivalent) or a change in
                  dose within 28 days of baseline.

               2. Treatment with more than 1 NSAID within 14 days at baseline.

               3. Methotrexate dose greater than 25 mg/week, or change in the dose of methotrexate
                  within 28 days of baseline.

               4. Subjects will be allowed to continue the following non biologic DMARDs:
                  sulfasalazine, hydroxychloroquine, and leflumomide. All other non-biologic DMARDs
                  (including but not limited to gold, penicillamine, azathioprine,
                  cyclophospamide), and biologic DMARDs must have been discontinued at least 2
                  months prior to Week 1.

               5. Any biologic B cell depleting agent (eg, rituximab) within 2 years of Week 1.

          2. Receipt of any live (attenuated) vaccine within 4 weeks prior to baseline.

          3. Receipt of any live (attenuated) vaccine within 4 weeks prior to baseline.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Santa Izabel - Santa Casa de Misericórdia da Bahia</name>
      <address>
        <city>Salvador</city>
        <state>Bahia</state>
        <zip>40050-410</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CIP (Centro Internacional de Pesquisa)</name>
      <address>
        <city>Goiania</city>
        <state>Goiás</state>
        <zip>74110-120</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CEPIC - Centro Paulista de Investigacao Clinica e Servicos Medicos LTDA</name>
      <address>
        <city>Sao Paulo</city>
        <state>SP</state>
        <zip>04209-003</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Center</name>
      <address>
        <city>Juiz de Fora</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Guangdong General Hospital</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510080</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chinese Academy of Medical Sciences - Peking Union Medical C</name>
      <address>
        <city>Beijing</city>
        <zip>100050</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shanghai Changning District Guanghua Hospital of Traditional Chinese and Western Medicine</name>
      <address>
        <city>Shanghai</city>
        <zip>200052</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shanghai Changhai Hospital[Rheumatology &amp;Immunology]</name>
      <address>
        <city>Shanghai</city>
        <zip>200433</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Integral de reumatolo[Gerencia / Representante Legal]</name>
      <address>
        <city>Barranquilla</city>
        <state>Atlántico</state>
        <zip>99999</zip>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fundacion Instituto de Reumatologia Fernando Chalem</name>
      <address>
        <city>Bogota DC</city>
        <state>Cundinamarca</state>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Pablo Tobon Uribe (HPTU)</name>
      <address>
        <city>Antioquia</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Revmatologicka poradna III. Interni nefrologicka, revmatologicka a endokrinologicka klinika</name>
      <address>
        <city>Olomouc</city>
        <zip>775 20</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Revmatologicky ustav</name>
      <address>
        <city>Praha 2</city>
        <zip>12850</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Revmatologicka ambulance</name>
      <address>
        <city>Praha 5</city>
        <zip>150 06</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PV-Medical s.r.o.</name>
      <address>
        <city>Zlin</city>
        <zip>760 01</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New University Hospital, Alexandria Clinical Research Center</name>
      <address>
        <city>Alexandria</city>
        <state>Al Iskandariyah</state>
        <zip>21131</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Al Azhar University Hospital [Rheumatology]</name>
      <address>
        <city>Cairo</city>
        <state>Al Qahirah</state>
        <zip>12111</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ain Shams University/Al Demerdash Hospital/Diabetology Unit</name>
      <address>
        <city>Cairo</city>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Budai Irgalmasrendi Korhaz</name>
      <address>
        <city>Budapest</city>
        <zip>1023</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Magyar Honvédség Egészségügyi Központ</name>
      <address>
        <city>Budapest</city>
        <zip>1062</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pharmaceutical Research Center- PRC. Jordan University of Science and Technology</name>
      <address>
        <city>Irbid</city>
        <zip>22110</zip>
        <country>Jordan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>American University of Beirut Medical Center</name>
      <address>
        <city>Beirut</city>
        <zip>1107-2020</zip>
        <country>Lebanon</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Queen Elizabeth Hospital</name>
      <address>
        <city>Kota Kinabalu</city>
        <state>Sabah</state>
        <zip>88586</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopsital Putrajaya [Medicine]</name>
      <address>
        <city>Putrajaya</city>
        <state>Wilayah Persekutuan Putrajaya</state>
        <zip>62250</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Malaysia Medical Centre</name>
      <address>
        <city>Kuala Lumpur</city>
        <zip>59100</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro de Investigación y Atención Integral de Durango, SC</name>
      <address>
        <city>Durango</city>
        <state>Durango / Mexico</state>
        <zip>34080</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro de Alta Especialidad en Reumatología e Investigación</name>
      <address>
        <city>San Luis de Potosi</city>
        <state>San Luis Potosí / Mexico</state>
        <zip>78213</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Medico Las Americas</name>
      <address>
        <city>Merida</city>
        <state>Yucatan</state>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Central</name>
      <address>
        <city>San Luis Potosi</city>
        <zip>78290</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>De La Salle University Health Sciences Campus- Clinical Epidemiology Unit</name>
      <address>
        <city>Dasmarinas</city>
        <state>Cavite</state>
        <zip>4114</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Luke's Mecical Center</name>
      <address>
        <city>Quezon</city>
        <state>Manila</state>
        <zip>1102</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Angeles University Foundation Medical Center</name>
      <address>
        <city>Angeles City</city>
        <state>Pampanga</state>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chong Hua Hospital, Medical Arts Center</name>
      <address>
        <city>Cebu City</city>
        <zip>6000</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UP-Philippine General Hospital, Medical Research Laboratory, Medicine Department,</name>
      <address>
        <city>Manila</city>
        <zip>1000</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hamad Medical Corporation</name>
      <address>
        <city>Doha</city>
        <zip>3050</zip>
        <country>Qatar</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spitalul Judetean</name>
      <address>
        <city>Baia Mare</city>
        <state>Maramure</state>
        <zip>4800</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spitalul Clinic Judetean de Urgenta Brasov</name>
      <address>
        <city>Brasov</city>
        <zip>500365</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spitalul Clinic de Recuperare</name>
      <address>
        <city>Iasi</city>
        <zip>700656</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spitalul Clinic Judetean de Urgenta Targu Mures</name>
      <address>
        <city>Tg Mures</city>
        <zip>540136</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LLC Research Medical Complex Your Health based on City Clinical Hospital Number 7(Legal address)</name>
      <address>
        <city>Kazan</city>
        <zip>420097</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LLC Research Medical Complex Your Health based on City Clinical Hospital Number 7 (Actual address)</name>
      <address>
        <city>Kazan</city>
        <zip>420137</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Krasnoyarsk State Medical University named after Professor V.F. Voyno-Yasenetsky</name>
      <address>
        <city>Krasnoyarsk</city>
        <zip>660014</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Krasnoyarsk State Medical University named after Professor V.F. Voyno-Yasenetsky,</name>
      <address>
        <city>Krasnoyarsk</city>
        <zip>660022</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FSBSI &quot;Scientific Research Institute of Rheumatology n. a. V.A. Nasonova&quot;</name>
      <address>
        <city>Moscow</city>
        <zip>115522</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LLC Institute of Medical Trials (Actual address)</name>
      <address>
        <city>St. Petersburg</city>
        <zip>196084</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitas Hospital [Cardiololgy]</name>
      <address>
        <city>Bloemfontein</city>
        <state>Free State</state>
        <zip>9301</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vincent Pallotti Hospital</name>
      <address>
        <city>Cape Town</city>
        <zip>7405</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Winelands Medical Research Centre</name>
      <address>
        <city>Stellenbosch</city>
        <zip>7600</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cathay General Hospital</name>
      <address>
        <city>Taiwan</city>
        <state>Taoyuan</state>
        <zip>330</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Buddhist Tzu Chi General Hospital - Dalin Branch</name>
      <address>
        <city>Chia-Yi</city>
        <zip>62247</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>China Medical University Hospital, Division of Rheumatology, Allergy and Immunology</name>
      <address>
        <city>Taichung</city>
        <zip>404</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Taipei Medical University Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>11042</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine,</name>
      <address>
        <city>Amphoe Mueang</city>
        <state>Chiang Mai</state>
        <zip>50200</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Siriraj Hospital [Rheumatology]</name>
      <address>
        <city>Bangkok</city>
        <zip>10700</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Khon Kaen University (KKU) - Faculty of Medicine</name>
      <address>
        <city>Khon Kaen</city>
        <zip>40002</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Songklanagarind Hospital</name>
      <address>
        <city>Songkla</city>
        <zip>90110</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Republican Clinical Hospital, Department of Internal Medicine #2 of Crimean State Medical University</name>
      <address>
        <city>Simferopol</city>
        <state>Crimea</state>
        <zip>95017</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Komunalnyi zaklad Kyivskoi oblasnoi rady &quot;Kyivska oblasna klinichna likarnia&quot;</name>
      <address>
        <city>Kyiv</city>
        <zip>04107</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Odessa Regional Clinical Hospital, Outpatient Department</name>
      <address>
        <city>Odessa</city>
        <zip>65025</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Municipal Institution of Ternopil Regional Council Ternopil University Hospital</name>
      <address>
        <city>Ternopil</city>
        <zip>46000</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vinnitsa Regional Clinical Hospital n.a. Pirogov, Department of Faculty Therapy of Vinnitsa NMU</name>
      <address>
        <city>Vinnitsa</city>
        <zip>21018</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Al Baraha Hospital</name>
      <address>
        <city>Dubai</city>
        <country>United Arab Emirates</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
    <country>China</country>
    <country>Colombia</country>
    <country>Czech Republic</country>
    <country>Egypt</country>
    <country>Hungary</country>
    <country>Jordan</country>
    <country>Lebanon</country>
    <country>Malaysia</country>
    <country>Mexico</country>
    <country>Philippines</country>
    <country>Qatar</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>South Africa</country>
    <country>Taiwan</country>
    <country>Thailand</country>
    <country>Ukraine</country>
    <country>United Arab Emirates</country>
  </location_countries>
  <removed_countries>
    <country>Saudi Arabia</country>
  </removed_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B1801315&amp;StudyName=Study%20conducted%20in%20subjects%20with%20rheumatoid%20arthritis%20who%20have%20moderate%20to%20severe%20disease%20activity%20despite%20methotrexate%20therapy%20with%20or%20</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>May 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 12, 2012</study_first_submitted>
  <study_first_submitted_qc>April 12, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 17, 2012</study_first_posted>
  <results_first_submitted>February 16, 2016</results_first_submitted>
  <results_first_submitted_qc>May 25, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 6, 2016</results_first_posted>
  <last_update_submitted>May 25, 2016</last_update_submitted>
  <last_update_submitted_qc>May 25, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 6, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>rheumatoid arthritis</keyword>
  <keyword>etanercept</keyword>
  <keyword>methotrexate</keyword>
  <keyword>DMARDs</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Etanercept</mesh_term>
    <mesh_term>Antirheumatic Agents</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The study consisted of Period 1 (an open-label, 24-week treat-to-target period), and Period 2 (a double-blind, randomized, 28-week period for participants who qualified for randomization).</recruitment_details>
      <pre_assignment_details>The study was conducted in participants with rheumatoid arthritis (RA) who had moderate to severe disease activity despite methotrexate (MTX) therapy (≥10 mg/week) with or without other non-biologic disease modifying anti-rheumatic drugs (DMARDs) for at least 12 weeks prior to screening.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Open-Label Treatment</title>
          <description>Participants in open-label treatment received Etanercept (ETN) 50 milligram (mg) once a week (QW) with MTX (with or without other DMARDs).</description>
        </group>
        <group group_id="P2">
          <title>Etanercept</title>
          <description>Participants were randomized to receive ETN 50 mg QW with MTX (with or without other DMARDs).</description>
        </group>
        <group group_id="P3">
          <title>Placebo</title>
          <description>Participants were randomized to receive PBO 50 mg QW + MTX (with or without DMARDs).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Period 1</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="489">491 participants were enrolled in open-label treatment but 2 did not receive study medication.</participants>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="452"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="37"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Insufficient Clinical Response</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Does Not Meet Entrance Criteria</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Study Terminated by Sponsor</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Period 2</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="167">Two participants in ETN did not receive treatment.</participants>
                <participants group_id="P3" count="176">One participants in PBO did not receive treatment.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="154"/>
                <participants group_id="P3" count="162"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="13"/>
                <participants group_id="P3" count="14"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Insufficient Clinical Response</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Study Terminated by Sponsor</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Unspecified Reasons</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The Full Analysis Set for Period 2 (Double Blind FAS) included all randomized participants who met the period 2 DAS28-ESR inclusion criteria, had at least one dose of study drug during Period 2 (ie, ETN, MTX or placebo) and have at least one valid efficacy (DAS28-ESR) evaluation after randomization.</population>
      <group_list>
        <group group_id="B1">
          <title>Etanercept</title>
          <description>Participants were randomized to receive ETN 50 mg QW with MTX (with or without other DMARDs).</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Participants were randomized to receive PBO 50 mg QW with MTX (with or without other DMARDs).</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="167"/>
            <count group_id="B2" value="176"/>
            <count group_id="B3" value="343"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46.2" spread="12.88"/>
                    <measurement group_id="B2" value="47.0" spread="12.02"/>
                    <measurement group_id="B3" value="46.6" spread="12.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="140"/>
                    <measurement group_id="B2" value="150"/>
                    <measurement group_id="B3" value="290"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Who Remained in Low Disease Activity (LDA) (Disease Activity Score in 28 Joints-erythrocyte Sedimentation Rate [DAS28-ESR] &lt;3.2) at Week 52.</title>
        <description>Proportion of participants who remained in LDA DAS28-ESR &lt;3.2 at Week 52 is presented below.</description>
        <time_frame>Baseline and Week 52</time_frame>
        <population>The FAS included all randomized participants who met the period 2 DAS28-ESR inclusion criteria, had at least one dose of study drug during Period 2 (ie, ETN, MTX or PBO) and had at least one valid efficacy (DAS28-ESR) evaluation after randomization.</population>
        <group_list>
          <group group_id="O1">
            <title>Etanercept</title>
            <description>Participants were randomized to receive ETN 50 mg QW with MTX (with or without other DMARDs).</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants were randomized to receive PBO 50 mg QW + MTX (with or without DMARDs).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Remained in Low Disease Activity (LDA) (Disease Activity Score in 28 Joints-erythrocyte Sedimentation Rate [DAS28-ESR] &lt;3.2) at Week 52.</title>
          <description>Proportion of participants who remained in LDA DAS28-ESR &lt;3.2 at Week 52 is presented below.</description>
          <population>The FAS included all randomized participants who met the period 2 DAS28-ESR inclusion criteria, had at least one dose of study drug during Period 2 (ie, ETN, MTX or PBO) and had at least one valid efficacy (DAS28-ESR) evaluation after randomization.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="163"/>
                <count group_id="O2" value="168"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.6"/>
                    <measurement group_id="O2" value="17.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Stratified by geographic region and disease status at randomization (Stratum 1=Remission: DAS28-ESR&lt;2.6 or Stratum 2=LDA: 2.6&lt;=DAS28-ESR&lt;3.2).</method_desc>
            <param_type>Difference in Proportions</param_type>
            <param_value>26.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>16.78</ci_lower_limit>
            <ci_upper_limit>35.81</ci_upper_limit>
            <estimate_desc>Participants who took rescue therapy had the final value taken before rescue used for analysis at all ensuing time points.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Who Remained in Remission at Week 52 (DAS28-ESR)</title>
        <description>Proportion of participants who remained in Remission (DAS28-ESR &lt;2.6) at Week 52.</description>
        <time_frame>Baseline and Week 52</time_frame>
        <population>The FAS included all randomized participants who met the period 2 DAS28-ESR inclusion criteria, had at least one dose of study drug during Period 2 (ie, ETN, MTX or PBO) and had at least one valid efficacy (DAS28-ESR) evaluation after randomization.</population>
        <group_list>
          <group group_id="O1">
            <title>Etanercept</title>
            <description>Participants were randomized to receive ETN 50 mg QW with MTX (with or without other DMARDs).</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants were randomized to receive PBO 50 mg QW + MTX (with or without DMARDs).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Remained in Remission at Week 52 (DAS28-ESR)</title>
          <description>Proportion of participants who remained in Remission (DAS28-ESR &lt;2.6) at Week 52.</description>
          <population>The FAS included all randomized participants who met the period 2 DAS28-ESR inclusion criteria, had at least one dose of study drug during Period 2 (ie, ETN, MTX or PBO) and had at least one valid efficacy (DAS28-ESR) evaluation after randomization.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="163"/>
                <count group_id="O2" value="168"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.2"/>
                    <measurement group_id="O2" value="29.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.019</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>The p-value from CMH test of general association was stratified by geographic region.</method_desc>
            <param_type>Difference in proportions</param_type>
            <param_value>23.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>6.83</ci_lower_limit>
            <ci_upper_limit>40.61</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving LDA (DAS28-ESR and DAS28-C-reactive Protein [CRP]) at Each Visit During Period 1</title>
        <description>Proportion of participants who achieved LDA (DAS28-ESR and DAS28-CRP at each visit during period 1 is presented below.</description>
        <time_frame>Baseline, Weeks 4, 8, 16 and 24</time_frame>
        <population>The FAS for Period 1 (Open Label FAS) included all randomized participants who had at least one dose of open label study drug during Period 1 (ie, ETN or MTX).</population>
        <group_list>
          <group group_id="O1">
            <title>Open-Label Treatment</title>
            <description>Participants in open-label treatment received ETN 50 mg QW with MTX (with or without other DMARDs).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving LDA (DAS28-ESR and DAS28-C-reactive Protein [CRP]) at Each Visit During Period 1</title>
          <description>Proportion of participants who achieved LDA (DAS28-ESR and DAS28-CRP at each visit during period 1 is presented below.</description>
          <population>The FAS for Period 1 (Open Label FAS) included all randomized participants who had at least one dose of open label study drug during Period 1 (ie, ETN or MTX).</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="478"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>DAS28-ESR Week 4 (N= 473)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-CRP Week 4 (N= 465)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-ESR Week 8 (N= 473)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-CRP Week 8 (N= 471)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-ESR Week 16 (N= 473)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-CRP Week 16 (N= 472)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-ESR Week 24 (N= 473)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-CRP Week 24 (N= 472)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving LDA (DAS28-ESR and DAS28-CRP) at Each Visit During Period 2</title>
        <description>Proportion of participants who achieved LDA (DAS28-ESR and DAS28-CRP at each visit during period 2 is presented below.</description>
        <time_frame>Baseline, Weeks 24, 28, 36, 44 and 52</time_frame>
        <population>The FAS included all randomized participants who met the period 2 DAS28-ESR inclusion criteria, had at least one dose of study drug during Period 2 (ie, ETN, MTX or PBO) and had at least one valid efficacy (DAS28-ESR) evaluation after randomization.</population>
        <group_list>
          <group group_id="O1">
            <title>Etanercept</title>
            <description>Participants were randomized to receive ETN 50 mg QW with MTX (with or without other DMARDs).</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants were randomized to receive PBO 50 mg QW + MTX (with or without DMARDs).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving LDA (DAS28-ESR and DAS28-CRP) at Each Visit During Period 2</title>
          <description>Proportion of participants who achieved LDA (DAS28-ESR and DAS28-CRP at each visit during period 2 is presented below.</description>
          <population>The FAS included all randomized participants who met the period 2 DAS28-ESR inclusion criteria, had at least one dose of study drug during Period 2 (ie, ETN, MTX or PBO) and had at least one valid efficacy (DAS28-ESR) evaluation after randomization.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="163"/>
                <count group_id="O2" value="168"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>DAS28-ESR Baseline (N= 163, 168)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-CRP Baseline (N= 163, 168)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-ESR Week 24 (N= 163, 168)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0"/>
                    <measurement group_id="O2" value="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-CRP Week 24 (N= 163, 168)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87.7"/>
                    <measurement group_id="O2" value="85.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-ESR Week 28 (N= 163, 168)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.6"/>
                    <measurement group_id="O2" value="41.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-CRP Week 28 (N= 160, 166)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.4"/>
                    <measurement group_id="O2" value="55.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-ESR Week 36 (N= 163, 168)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.2"/>
                    <measurement group_id="O2" value="24.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-CRP Week 36 (N= 162, 167)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.1"/>
                    <measurement group_id="O2" value="41.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-ESR Week 44 (N= 163, 168)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.5"/>
                    <measurement group_id="O2" value="20.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-CRP Week 44 (N= 162, 167)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.1"/>
                    <measurement group_id="O2" value="38.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-ESR Week 52 (N= 163, 168)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.6"/>
                    <measurement group_id="O2" value="17.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-CRP Week 52 (N= 162, 167)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64.2"/>
                    <measurement group_id="O2" value="37.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>DAS28-ESR Baseline</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.371</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Stratified by geographic region and disease status at randomization (Stratum 1=Remission: DAS28-ESR&lt;2.6 or Stratum 2=LDA: 2.6&lt;=DAS28-ESR&lt;3.2).</method_desc>
            <param_type>Difference in proportions</param_type>
            <param_value>-0.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.76</ci_lower_limit>
            <ci_upper_limit>0.57</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>DAS28-CRP Baseline</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.358</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Stratified by geographic region and disease status at randomization (Stratum 1=Remission: DAS28-ESR&lt;2.6 or Stratum 2=LDA: 2.6&lt;=DAS28-ESR&lt;3.2).</method_desc>
            <param_type>Difference in proportions</param_type>
            <param_value>0.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.59</ci_lower_limit>
            <ci_upper_limit>1.81</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>DAS28-CRP Week 24</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.667</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Stratified by geographic region and disease status at randomization (Stratum 1=Remission: DAS28-ESR&lt;2.6 or Stratum 2=LDA: 2.6&lt;=DAS28-ESR&lt;3.2).</method_desc>
            <param_type>Difference in proportions</param_type>
            <param_value>2.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.76</ci_lower_limit>
            <ci_upper_limit>9.98</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>DAS28-ESR Week 28</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Stratified by geographic region and disease status at randomization (Stratum 1=Remission: DAS28-ESR&lt;2.6 or Stratum 2=LDA: 2.6&lt;=DAS28-ESR&lt;3.2).</method_desc>
            <param_type>Difference in proportions</param_type>
            <param_value>21.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>10.99</ci_lower_limit>
            <ci_upper_limit>32.02</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>DAS28-CRP Week 28</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.004</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Stratified by geographic region and disease status at randomization (Stratum 1=Remission: DAS28-ESR&lt;2.6 or Stratum 2=LDA: 2.6&lt;=DAS28-ESR&lt;3.2).</method_desc>
            <param_type>Difference in proportions</param_type>
            <param_value>19.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>8.81</ci_lower_limit>
            <ci_upper_limit>29.10</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>DAS28-ESR Week 36</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Stratified by geographic region and disease status at randomization (Stratum 1=Remission: DAS28-ESR&lt;2.6 or Stratum 2=LDA: 2.6&lt;=DAS28-ESR&lt;3.2).</method_desc>
            <param_type>Difference in proportions</param_type>
            <param_value>30.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>20.79</ci_lower_limit>
            <ci_upper_limit>40.83</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>DAS28-CRP Week 36</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Stratified by geographic region and disease status at randomization (Stratum 1=Remission: DAS28-ESR&lt;2.6 or Stratum 2=LDA: 2.6&lt;=DAS28-ESR&lt;3.2).</method_desc>
            <param_type>Difference in proportions</param_type>
            <param_value>27.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>16.89</ci_lower_limit>
            <ci_upper_limit>37.54</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>DAS28-ESR Week 44</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Stratified by geographic region and disease status at randomization (Stratum 1=Remission: DAS28-ESR&lt;2.6 or Stratum 2=LDA: 2.6&lt;=DAS28-ESR&lt;3.2).</method_desc>
            <param_type>Difference in proportions</param_type>
            <param_value>31.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>21.51</ci_lower_limit>
            <ci_upper_limit>41.08</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>DAS28-CRP Week 44</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Stratified by geographic region and disease status at randomization (Stratum 1=Remission: DAS28-ESR&lt;2.6 or Stratum 2=LDA: 2.6&lt;=DAS28-ESR&lt;3.2).</method_desc>
            <param_type>Difference in proportions</param_type>
            <param_value>30.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>19.95</ci_lower_limit>
            <ci_upper_limit>40.47</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>DAS28-ESR Week 52</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Stratified by geographic region and disease status at randomization (Stratum 1=Remission: DAS28-ESR&lt;2.6 or Stratum 2=LDA: 2.6&lt;=DAS28-ESR&lt;3.2).</method_desc>
            <param_type>Difference in proportions</param_type>
            <param_value>26.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>16.78</ci_lower_limit>
            <ci_upper_limit>35.81</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>DAS28-CRP Week 52</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Stratified by geographic region and disease status at randomization (Stratum 1=Remission: DAS28-ESR&lt;2.6 or Stratum 2=LDA: 2.6&lt;=DAS28-ESR&lt;3.2).</method_desc>
            <param_type>Difference in proportions</param_type>
            <param_value>27.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>16.67</ci_lower_limit>
            <ci_upper_limit>37.47</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving Remission (DAS28-ESR and DAS28-CRP) at Each Visit During Period 1</title>
        <description>Proportion of participants who achieved remission (DAS28-ESR and DAS28-CRP at each visit during period 1 is presented below.</description>
        <time_frame>Baseline, Weeks 4, 8, 16 and 24</time_frame>
        <population>The FAS for Period 1 (Open Label FAS) included all randomized participants who had at least one dose of open label study drug during Period 1 (ie, ETN or MTX).</population>
        <group_list>
          <group group_id="O1">
            <title>Open-Label Treatment</title>
            <description>Participants in open-label treatment received ETN 50 mg QW with MTX (with or without other DMARDs).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving Remission (DAS28-ESR and DAS28-CRP) at Each Visit During Period 1</title>
          <description>Proportion of participants who achieved remission (DAS28-ESR and DAS28-CRP at each visit during period 1 is presented below.</description>
          <population>The FAS for Period 1 (Open Label FAS) included all randomized participants who had at least one dose of open label study drug during Period 1 (ie, ETN or MTX).</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="478"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>DAS28-ESR Week 4 (N= 473)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-CRP Week 4 (N= 465)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-ESR Week 8 (N= 473)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-CRP Week 8 (N= 471)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-ESR Week 16 (N= 473)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-CRP Week 16 (N= 472)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-ESR Week 24 (N= 473)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-CRP Week 24 (N= 472)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving Remission (DAS28-ESR and DAS28-CRP) at Each Visit During Period 2</title>
        <description>Proportion of participants who achieved LDA (DAS28-ESR and DAS28-CRP at each visit during period 2 is presented below.</description>
        <time_frame>Baseline, Weeks 24, 28, 36, 44 and 52</time_frame>
        <population>The FAS included all randomized participants who met the period 2 DAS28-ESR inclusion criteria, had at least one dose of study drug during Period 2 (ie, ETN, MTX or PBO) and had at least one valid efficacy (DAS28-ESR) evaluation after randomization.</population>
        <group_list>
          <group group_id="O1">
            <title>Etanercept</title>
            <description>Participants were randomized to receive ETN 50 mg QW with MTX (with or without other DMARDs).</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants were randomized to receive PBO 50 mg QW + MTX (with or without DMARDs).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving Remission (DAS28-ESR and DAS28-CRP) at Each Visit During Period 2</title>
          <description>Proportion of participants who achieved LDA (DAS28-ESR and DAS28-CRP at each visit during period 2 is presented below.</description>
          <population>The FAS included all randomized participants who met the period 2 DAS28-ESR inclusion criteria, had at least one dose of study drug during Period 2 (ie, ETN, MTX or PBO) and had at least one valid efficacy (DAS28-ESR) evaluation after randomization.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="163"/>
                <count group_id="O2" value="168"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>DAS28-ESR Baseline (N= 163, 168)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-CRP Baseline (N= 163, 168)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-ESR Week 24 (N= 163, 168)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.0"/>
                    <measurement group_id="O2" value="36.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-CRP Week 24 (N= 163, 168)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64.4"/>
                    <measurement group_id="O2" value="63.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-ESR Week 28 (N= 163, 168)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.5"/>
                    <measurement group_id="O2" value="20.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-CRP Week 28 (N= 160, 166)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.9"/>
                    <measurement group_id="O2" value="34.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-ESR Week 36 (N= 163, 168)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.9"/>
                    <measurement group_id="O2" value="17.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-CRP Week 36 (N= 162, 167)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.0"/>
                    <measurement group_id="O2" value="25.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-ESR Week 44 (N= 163, 168)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.7"/>
                    <measurement group_id="O2" value="11.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-CRP Week 44 (N= 162, 167)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.9"/>
                    <measurement group_id="O2" value="21.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-ESR Week 52 (N= 163, 168)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.7"/>
                    <measurement group_id="O2" value="13.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-CRP Week 52 (N= 162, 167)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.9"/>
                    <measurement group_id="O2" value="19.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>DAS28-CRP Week 24</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.774</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Stratified by geographic region and disease status at randomization (Stratum 1=Remission: DAS28-ESR&lt;2.6 or Stratum 2=LDA: 2.6&lt;=DAS28-ESR&lt;3.2).</method_desc>
            <param_type>Difference in proportions</param_type>
            <param_value>1.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-9.03</ci_lower_limit>
            <ci_upper_limit>11.68</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>DAS28-ESR Week 28</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.034</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Stratified by geographic region and disease status at randomization (Stratum 1=Remission: DAS28-ESR&lt;2.6 or Stratum 2=LDA: 2.6&lt;=DAS28-ESR&lt;3.2).</method_desc>
            <param_type>Difference in proportions</param_type>
            <param_value>12.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.86</ci_lower_limit>
            <ci_upper_limit>21.69</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>DAS28-CRP Week 28</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.020</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Stratified by geographic region and disease status at randomization (Stratum 1=Remission: DAS28-ESR&lt;2.6 or Stratum 2=LDA: 2.6&lt;=DAS28-ESR&lt;3.2).</method_desc>
            <param_type>Difference in proportions</param_type>
            <param_value>16.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>6.33</ci_lower_limit>
            <ci_upper_limit>27.54</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>DAS28-ESR Week 36</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.007</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Stratified by geographic region and disease status at randomization (Stratum 1=Remission: DAS28-ESR&lt;2.6 or Stratum 2=LDA: 2.6&lt;=DAS28-ESR&lt;3.2).</method_desc>
            <param_type>Difference in proportions</param_type>
            <param_value>14.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>5.48</ci_lower_limit>
            <ci_upper_limit>23.80</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>DAS28-CRP Week 36</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Stratified by geographic region and disease status at randomization (Stratum 1=Remission: DAS28-ESR&lt;2.6 or Stratum 2=LDA: 2.6&lt;=DAS28-ESR&lt;3.2).</method_desc>
            <param_type>Difference in proportions</param_type>
            <param_value>24.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>14.72</ci_lower_limit>
            <ci_upper_limit>34.98</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>DAS28-ESR Week 44</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Stratified by geographic region and disease status at randomization (Stratum 1=Remission: DAS28-ESR&lt;2.6 or Stratum 2=LDA: 2.6&lt;=DAS28-ESR&lt;3.2).</method_desc>
            <param_type>Difference in proportions</param_type>
            <param_value>18.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>10.16</ci_lower_limit>
            <ci_upper_limit>27.38</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>DAS28-CRP Week 44</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Stratified by geographic region and disease status at randomization (Stratum 1=Remission: DAS28-ESR&lt;2.6 or Stratum 2=LDA: 2.6&lt;=DAS28-ESR&lt;3.2).</method_desc>
            <param_type>Difference in proportions</param_type>
            <param_value>30.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>21.03</ci_lower_limit>
            <ci_upper_limit>40.76</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>DAS28-ESR Week 52</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Stratified by geographic region and disease status at randomization (Stratum 1=Remission: DAS28-ESR&lt;2.6 or Stratum 2=LDA: 2.6&lt;=DAS28-ESR&lt;3.2).</method_desc>
            <param_type>Difference in proportions</param_type>
            <param_value>20.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>11.78</ci_lower_limit>
            <ci_upper_limit>29.52</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>DAS28-CRP Week 52</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Stratified by geographic region and disease status at randomization (Stratum 1=Remission: DAS28-ESR&lt;2.6 or Stratum 2=LDA: 2.6&lt;=DAS28-ESR&lt;3.2).</method_desc>
            <param_type>Difference in proportions</param_type>
            <param_value>27.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>17.38</ci_lower_limit>
            <ci_upper_limit>36.93</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in DAS28-CRP and DAS28-ESR in Period 1</title>
        <description>The DAS assessment is a derived measurement with differential weight given to each component. The DAS28-ESR and DAS28-CRP was calculated at every visit within the clinical database in period 1. The components of the DAS28 ESR score assessment are: Tender/ Painful Joint Count (28), Swollen Joint Count (28); ESR, Subject General Health VAS assessment. The components of the DAS28 CRP score assessment were: Tender/Painful Joint Count (28); Swollen Joint Count (28), hsCRP, and the Subject General Health VAS assessment. This efficacy measurement was made at every study visit.</description>
        <time_frame>Baseline, Weeks 4, 8, 16 and 24</time_frame>
        <population>The FAS for Period 1 (Open Label FAS) included all randomized participants who had at least one dose of open label study drug during Period 1 (ie, ETN or MTX).</population>
        <group_list>
          <group group_id="O1">
            <title>Open-Label Treatment</title>
            <description>Participants in open-label treatment received ETN 50 mg QW with MTX (with or without other DMARDs).</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in DAS28-CRP and DAS28-ESR in Period 1</title>
          <description>The DAS assessment is a derived measurement with differential weight given to each component. The DAS28-ESR and DAS28-CRP was calculated at every visit within the clinical database in period 1. The components of the DAS28 ESR score assessment are: Tender/ Painful Joint Count (28), Swollen Joint Count (28); ESR, Subject General Health VAS assessment. The components of the DAS28 CRP score assessment were: Tender/Painful Joint Count (28); Swollen Joint Count (28), hsCRP, and the Subject General Health VAS assessment. This efficacy measurement was made at every study visit.</description>
          <population>The FAS for Period 1 (Open Label FAS) included all randomized participants who had at least one dose of open label study drug during Period 1 (ie, ETN or MTX).</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="478"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>DAS28-ESR Week 4 (N= 473)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.61" spread="1.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-CRP Week 4 (N= 465)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.61" spread="1.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-ESR Week 8 (N= 473)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.14" spread="1.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-CRP Week 8 (N= 471)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.09" spread="1.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-ESR Week 16 (N= 473)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.62" spread="1.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-CRP Week 16 (N= 472)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.54" spread="1.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-ESR Week 24 (N= 473)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.23" spread="1.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-CRP Week 24 (N= 472)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.95" spread="1.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in DAS28-CRP and DAS28-ESR in Period 2</title>
        <description>The DAS assessment is a derived measurement with differential weight given to each component. The DAS28-ESR and DAS28-CRP was calculated at every visit within the clinical database in period 2. The components of the DAS28 ESR score assessment are: Tender/ Painful Joint Count (28), Swollen Joint Count (28); ESR, Subject General Health VAS assessment. The components of the DAS28 CRP score assessment were: Tender/Painful Joint Count (28); Swollen Joint Count (28), hsCRP, and the Subject General Health VAS assessment. This efficacy measurement was made at every study visit.</description>
        <time_frame>Baseline, Weeks 24, 28, 36, 44 and 52</time_frame>
        <population>The FAS included all randomized participants who met the period 2 DAS28-ESR inclusion criteria, had at least one dose of study drug during Period 2 (ie, ETN, MTX or PBO) and had at least one valid efficacy (DAS28-ESR) evaluation after randomization.</population>
        <group_list>
          <group group_id="O1">
            <title>Etanercept</title>
            <description>Participants were randomized to receive ETN 50 mg QW with MTX (with or without other DMARDs).</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants were randomized to receive PBO 50 mg QW + MTX (with or without DMARDs).</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in DAS28-CRP and DAS28-ESR in Period 2</title>
          <description>The DAS assessment is a derived measurement with differential weight given to each component. The DAS28-ESR and DAS28-CRP was calculated at every visit within the clinical database in period 2. The components of the DAS28 ESR score assessment are: Tender/ Painful Joint Count (28), Swollen Joint Count (28); ESR, Subject General Health VAS assessment. The components of the DAS28 CRP score assessment were: Tender/Painful Joint Count (28); Swollen Joint Count (28), hsCRP, and the Subject General Health VAS assessment. This efficacy measurement was made at every study visit.</description>
          <population>The FAS included all randomized participants who met the period 2 DAS28-ESR inclusion criteria, had at least one dose of study drug during Period 2 (ie, ETN, MTX or PBO) and had at least one valid efficacy (DAS28-ESR) evaluation after randomization.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="163"/>
                <count group_id="O2" value="168"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>DAS28-ESR Week 24 (N= 163, 168)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.79" spread="1.04"/>
                    <measurement group_id="O2" value="-3.70" spread="0.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-CRP Week 24 (N= 163, 168)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.36" spread="1.03"/>
                    <measurement group_id="O2" value="-3.32" spread="1.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-ESR Week 28 (N= 163, 168)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.35" spread="1.31"/>
                    <measurement group_id="O2" value="-2.73" spread="1.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-CRP Week 28 (N= 160, 166)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.06" spread="1.26"/>
                    <measurement group_id="O2" value="-2.53" spread="1.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-ESR Week 36 (N= 163, 168)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.20" spread="1.40"/>
                    <measurement group_id="O2" value="-2.40" spread="1.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-CRP Week 36 (N= 162, 167)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.97" spread="1.35"/>
                    <measurement group_id="O2" value="-2.27" spread="1.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-ESR Week 44 (N= 163, 168)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.15" spread="1.36"/>
                    <measurement group_id="O2" value="-2.31" spread="1.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-CRP Week 44 (N= 162, 167)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.95" spread="1.35"/>
                    <measurement group_id="O2" value="-2.19" spread="1.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-ESR Week 52 (N= 163, 168)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.08" spread="1.40"/>
                    <measurement group_id="O2" value="-2.28" spread="1.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28-CRP Week 52 (N= 162, 167)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.92" spread="1.36"/>
                    <measurement group_id="O2" value="-2.16" spread="1.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>DAS28-ESR Week 28</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <method_desc>Stratified by geographic region and disease status at randomization (Stratum 1=Remission: DAS28-ESR&lt;2.6 or Stratum 2=LDA: 2.6&lt;=DAS28-ESR&lt;3.2).</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.47</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.73</ci_lower_limit>
            <ci_upper_limit>-0.20</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>DAS28-CRP Week 28</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.006</p_value>
            <method>ANCOVA</method>
            <method_desc>Stratified by geographic region and disease status at randomization (Stratum 1=Remission: DAS28-ESR&lt;2.6 or Stratum 2=LDA: 2.6&lt;=DAS28-ESR&lt;3.2).</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.36</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.61</ci_lower_limit>
            <ci_upper_limit>-0.11</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>DAS28-ESR Week 36</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <method_desc>Stratified by geographic region and disease status at randomization (Stratum 1=Remission: DAS28-ESR&lt;2.6 or Stratum 2=LDA: 2.6&lt;=DAS28-ESR&lt;3.2).</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.68</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.96</ci_lower_limit>
            <ci_upper_limit>-0.39</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>DAS28-CRP Week 36</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <method_desc>Stratified by geographic region and disease status at randomization (Stratum 1=Remission: DAS28-ESR&lt;2.6 or Stratum 2=LDA: 2.6&lt;=DAS28-ESR&lt;3.2).</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.55</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.82</ci_lower_limit>
            <ci_upper_limit>-0.28</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>DAS28-ESR Week 44</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <method_desc>Stratified by geographic region and disease status at randomization (Stratum 1=Remission: DAS28-ESR&lt;2.6 or Stratum 2=LDA: 2.6&lt;=DAS28-ESR&lt;3.2).</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.75</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.03</ci_lower_limit>
            <ci_upper_limit>-0.46</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>DAS28-CRP Week 44</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <method_desc>Stratified by geographic region and disease status at randomization (Stratum 1=Remission: DAS28-ESR&lt;2.6 or Stratum 2=LDA: 2.6&lt;=DAS28-ESR&lt;3.2).</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.65</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.92</ci_lower_limit>
            <ci_upper_limit>-0.37</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>DAS28-ESR Week 52</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <method_desc>Stratified by geographic region and disease status at randomization (Stratum 1=Remission: DAS28-ESR&lt;2.6 or Stratum 2=LDA: 2.6&lt;=DAS28-ESR&lt;3.2).</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.69</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.98</ci_lower_limit>
            <ci_upper_limit>-0.40</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>DAS28-CRP Week 52</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <method_desc>Stratified by geographic region and disease status at randomization (Stratum 1=Remission: DAS28-ESR&lt;2.6 or Stratum 2=LDA: 2.6&lt;=DAS28-ESR&lt;3.2).</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.64</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.91</ci_lower_limit>
            <ci_upper_limit>-0.36</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Who Had a Recurrence of Disease Symptoms During Period 2, Based on the Protocol Criteria</title>
        <description>Flare is defined as the criteria of loss of LDA plus ≥0.6 unit worsening in DAS28-ESR score during period 2.</description>
        <time_frame>Baseline and Week 52</time_frame>
        <population>The FAS included all randomized participants who met the period 2 DAS28-ESR inclusion criteria, had at least one dose of study drug during Period 2 (ie, ETN, MTX or PBO) and had at least one valid efficacy (DAS28-ESR) evaluation after randomization.</population>
        <group_list>
          <group group_id="O1">
            <title>Etanercept</title>
            <description>Participants were randomized to receive ETN 50 mg QW with MTX (with or without other DMARDs).</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants were randomized to receive PBO 50 mg QW + MTX (with or without DMARDs).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Had a Recurrence of Disease Symptoms During Period 2, Based on the Protocol Criteria</title>
          <description>Flare is defined as the criteria of loss of LDA plus ≥0.6 unit worsening in DAS28-ESR score during period 2.</description>
          <population>The FAS included all randomized participants who met the period 2 DAS28-ESR inclusion criteria, had at least one dose of study drug during Period 2 (ie, ETN, MTX or PBO) and had at least one valid efficacy (DAS28-ESR) evaluation after randomization.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="163"/>
                <count group_id="O2" value="168"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.1"/>
                    <measurement group_id="O2" value="79.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Log Rank</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving European League Against Rheumatism (EULAR) Good and or Moderate Responses (by Both DAS28-ESR and DAS28-CRP Scores) at Each Visit During Period 1.</title>
        <description>EULAR response is based on DAS28-ESR scores. The following good and moderate response is defined based on DAS28-ESR at endpoint (DAS28-ESR improvement at from Baseline in parenthesis): ≤3.2 units (&gt;1.2 units) is good response; ≤3.2 units (0.6-1.2 units) are moderate response; ≤3.2 units (≤0.6 units) are no response.</description>
        <time_frame>Baseline, Weeks 4, 8, 16 and 24</time_frame>
        <population>The FAS for Period 1 (Open Label FAS) included all randomized participants who had at least one dose of open label study drug during Period 1 (ie, ETN or MTX).</population>
        <group_list>
          <group group_id="O1">
            <title>Open-Label Treatment</title>
            <description>Participants in open-label treatment received ETN 50 mg QW with MTX (with or without other DMARDs).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving European League Against Rheumatism (EULAR) Good and or Moderate Responses (by Both DAS28-ESR and DAS28-CRP Scores) at Each Visit During Period 1.</title>
          <description>EULAR response is based on DAS28-ESR scores. The following good and moderate response is defined based on DAS28-ESR at endpoint (DAS28-ESR improvement at from Baseline in parenthesis): ≤3.2 units (&gt;1.2 units) is good response; ≤3.2 units (0.6-1.2 units) are moderate response; ≤3.2 units (≤0.6 units) are no response.</description>
          <population>The FAS for Period 1 (Open Label FAS) included all randomized participants who had at least one dose of open label study drug during Period 1 (ie, ETN or MTX).</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="478"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Good Response: DAS28-ESR Week 4 (N= 473)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Good Response: DAS28-CRP Week 4 (N= 465)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Good Response: DAS28-ESR Week 8 (N= 473)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Good Response: DAS28-CRP Week 8 (N= 471)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Good Response: DAS28-ESR Week 16 (N= 473)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Good Response: DAS28-CRP Week 16 (N= 472)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Good Response: DAS28-ESR Week 24 (N= 473)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Good Response: DAS28-CRP Week 24 (N= 472)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate Response: DAS28-ESR Week 4 (N= 473)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate Response: DAS28-CRP Week 4 (N= 465)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate Response: DAS28-ESR Week 8 (N= 473)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate Response: DAS28-CRP Week 8 (N= 471)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate Response: DAS28-ESR Week 16 (N= 473)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate Response: DAS28-CRP Week 16 (N= 472)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate Response: DAS28-ESR Week 24 (N= 473)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate Response: DAS28-CRP Week 24 (N= 472)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving EULAR Good and or Moderate Responses (by Both DAS28-ESR and DAS28-CRP Scores) at Each Visit During Period 2.</title>
        <description>EULAR response is based on DAS28-ESR scores. The following good and moderate response is defined based on DAS28-ESR at endpoint (DAS28-ESR improvement at from Baseline in parenthesis): ≤3.2 units (&gt;1.2 units) is good response; ≤3.2 units (0.6-1.2 units) are moderate response; ≤3.2 units (≤0.6 units) are no response.</description>
        <time_frame>Baseline, Weeks 24, 28, 36, 44 and 52</time_frame>
        <population>The FAS included all randomized participants who met the period 2 DAS28-ESR inclusion criteria, had at least one dose of study drug during Period 2 (ie, ETN, MTX or PBO) and had at least one valid efficacy (DAS28-ESR) evaluation after randomization.</population>
        <group_list>
          <group group_id="O1">
            <title>Etanercept</title>
            <description>Participants were randomized to receive ETN 50 mg QW with MTX (with or without other DMARDs).</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants were randomized to receive PBO 50 mg QW + MTX (with or without DMARDs).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving EULAR Good and or Moderate Responses (by Both DAS28-ESR and DAS28-CRP Scores) at Each Visit During Period 2.</title>
          <description>EULAR response is based on DAS28-ESR scores. The following good and moderate response is defined based on DAS28-ESR at endpoint (DAS28-ESR improvement at from Baseline in parenthesis): ≤3.2 units (&gt;1.2 units) is good response; ≤3.2 units (0.6-1.2 units) are moderate response; ≤3.2 units (≤0.6 units) are no response.</description>
          <population>The FAS included all randomized participants who met the period 2 DAS28-ESR inclusion criteria, had at least one dose of study drug during Period 2 (ie, ETN, MTX or PBO) and had at least one valid efficacy (DAS28-ESR) evaluation after randomization.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="163"/>
                <count group_id="O2" value="168"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Good Response: DAS28-ESR Week 24 (N= 163, 168)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.4"/>
                    <measurement group_id="O2" value="99.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Good Response: DAS28-CRP Week 24 (N= 163, 168)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86.5"/>
                    <measurement group_id="O2" value="85.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Good Response: DAS28-ESR Week 28 (N= 163, 168)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.6"/>
                    <measurement group_id="O2" value="41.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Good Response: DAS28-CRP Week 28 (N= 160, 166)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.1"/>
                    <measurement group_id="O2" value="54.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Good Response: DAS28-ESR Week 36 (N= 163, 168)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.2"/>
                    <measurement group_id="O2" value="23.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Good Response: DAS28-CRP Week 36 (N= 162, 167)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.9"/>
                    <measurement group_id="O2" value="40.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Good Response: DAS28-ESR Week 44 (N= 163, 168)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.9"/>
                    <measurement group_id="O2" value="19.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Good Response: DAS28-CRP Week 44 (N= 162, 167)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.5"/>
                    <measurement group_id="O2" value="37.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Good Response: DAS28-ESR Week 52 (N= 163, 168)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.9"/>
                    <measurement group_id="O2" value="16.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Good Response: DAS28-CRP Week 52 (N= 162, 167)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.0"/>
                    <measurement group_id="O2" value="35.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate Response: DAS28-ESR Week 24 (N= 163, 168)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0"/>
                    <measurement group_id="O2" value="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate Response: DAS28-CRP Week 24 (N= 163, 168)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0"/>
                    <measurement group_id="O2" value="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate Response: DAS28-ESR Week 28 (N= 163, 168)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95.7"/>
                    <measurement group_id="O2" value="87.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate Response: DAS28-CRP Week 28 (N= 160, 166)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.9"/>
                    <measurement group_id="O2" value="90.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate Response: DAS28-ESR Week 36 (N= 163, 168)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93.9"/>
                    <measurement group_id="O2" value="83.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate Response: DAS28-CRP Week 36 (N= 162, 167)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.4"/>
                    <measurement group_id="O2" value="85.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate Response: DAS28-ESR Week 44 (N= 163, 168)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93.3"/>
                    <measurement group_id="O2" value="81.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate Response: DAS28-CRP Week 44 (N= 162, 167)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95.1"/>
                    <measurement group_id="O2" value="84.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate Response: DAS28-ESR Week 52 (N= 163, 168)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93.3"/>
                    <measurement group_id="O2" value="82.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate Response: DAS28-CRP Week 52 (N= 162, 167)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95.7"/>
                    <measurement group_id="O2" value="84.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Good Response: DAS28-CRP Week 24</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.961</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Stratified by geographic region and disease status at randomization (Stratum 1=Remission: DAS28-ESR&lt;2.6 or Stratum 2=LDA: 2.6&lt;=DAS28-ESR&lt;3.2).</method_desc>
            <param_type>Difference in proportions</param_type>
            <param_value>1.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.13</ci_lower_limit>
            <ci_upper_limit>8.90</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Good Response: DAS28-ESR Week 28</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Stratified by geographic region and disease status at randomization (Stratum 1=Remission: DAS28-ESR&lt;2.6 or Stratum 2=LDA: 2.6&lt;=DAS28-ESR&lt;3.2).</method_desc>
            <param_type>Difference in proportions</param_type>
            <param_value>21.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>10.99</ci_lower_limit>
            <ci_upper_limit>32.02</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Good Response: DAS28-CRP Week 28</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.007</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Stratified by geographic region and disease status at randomization (Stratum 1=Remission: DAS28-ESR&lt;2.6 or Stratum 2=LDA: 2.6&lt;=DAS28-ESR&lt;3.2).</method_desc>
            <param_type>Difference in proportions</param_type>
            <param_value>18.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>8.08</ci_lower_limit>
            <ci_upper_limit>28.53</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Good Response: DAS28-ESR Week 36</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Stratified by geographic region and disease status at randomization (Stratum 1=Remission: DAS28-ESR&lt;2.6 or Stratum 2=LDA: 2.6&lt;=DAS28-ESR&lt;3.2).</method_desc>
            <param_type>Difference in proportions</param_type>
            <param_value>31.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>21.42</ci_lower_limit>
            <ci_upper_limit>41.39</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Good Response: DAS28-CRP Week 36</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Stratified by geographic region and disease status at randomization (Stratum 1=Remission: DAS28-ESR&lt;2.6 or Stratum 2=LDA: 2.6&lt;=DAS28-ESR&lt;3.2).</method_desc>
            <param_type>Difference in proportions</param_type>
            <param_value>27.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>16.83</ci_lower_limit>
            <ci_upper_limit>37.54</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Good Response: DAS28-ESR Week 44</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Stratified by geographic region and disease status at randomization (Stratum 1=Remission: DAS28-ESR&lt;2.6 or Stratum 2=LDA: 2.6&lt;=DAS28-ESR&lt;3.2).</method_desc>
            <param_type>Difference in proportions</param_type>
            <param_value>31.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>21.53</ci_lower_limit>
            <ci_upper_limit>41.02</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Good Response: DAS28-CRP Week 44</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Stratified by geographic region and disease status at randomization (Stratum 1=Remission: DAS28-ESR&lt;2.6 or Stratum 2=LDA: 2.6&lt;=DAS28-ESR&lt;3.2).</method_desc>
            <param_type>Difference in proportions</param_type>
            <param_value>30.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>20.54</ci_lower_limit>
            <ci_upper_limit>41.05</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Good Response: DAS28-ESR Week 52</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Stratified by geographic region and disease status at randomization (Stratum 1=Remission: DAS28-ESR&lt;2.6 or Stratum 2=LDA: 2.6&lt;=DAS28-ESR&lt;3.2).</method_desc>
            <param_type>Difference in proportions</param_type>
            <param_value>26.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>16.82</ci_lower_limit>
            <ci_upper_limit>35.74</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Good Response: DAS28-CRP Week 52</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Stratified by geographic region and disease status at randomization (Stratum 1=Remission: DAS28-ESR&lt;2.6 or Stratum 2=LDA: 2.6&lt;=DAS28-ESR&lt;3.2).</method_desc>
            <param_type>Difference in proportions</param_type>
            <param_value>27.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>16.63</ci_lower_limit>
            <ci_upper_limit>37.44</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Good Response: DAS28-ESR Week 24</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.766</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Stratified by geographic region and disease status at randomization (Stratum 1=Remission: DAS28-ESR&lt;2.6 or Stratum 2=LDA: 2.6&lt;=DAS28-ESR&lt;3.2).</method_desc>
            <param_type>Difference in Proportions</param_type>
            <param_value>-0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.69</ci_lower_limit>
            <ci_upper_limit>1.65</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Moderate Response: DAS28-ESR Week 28</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.091</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Stratified by geographic region and disease status at randomization (Stratum 1=Remission: DAS28-ESR&lt;2.6 or Stratum 2=LDA: 2.6&lt;=DAS28-ESR&lt;3.2).</method_desc>
            <param_type>Difference in Proportions</param_type>
            <param_value>8.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.32</ci_lower_limit>
            <ci_upper_limit>14.10</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Moderate Response: DAS28-CRP Week 28</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.227</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Stratified by geographic region and disease status at randomization (Stratum 1=Remission: DAS28-ESR&lt;2.6 or Stratum 2=LDA: 2.6&lt;=DAS28-ESR&lt;3.2).</method_desc>
            <param_type>Difference in proportions</param_type>
            <param_value>6.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.28</ci_lower_limit>
            <ci_upper_limit>11.75</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Moderate Response: DAS28-ESR Week 36</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.072</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Stratified by geographic region and disease status at randomization (Stratum 1=Remission: DAS28-ESR&lt;2.6 or Stratum 2=LDA: 2.6&lt;=DAS28-ESR&lt;3.2).</method_desc>
            <param_type>Difference in proportions</param_type>
            <param_value>9.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>3.27</ci_lower_limit>
            <ci_upper_limit>16.60</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Moderate Response: DAS28-CRP Week 36</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.108</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Stratified by geographic region and disease status at randomization (Stratum 1=Remission: DAS28-ESR&lt;2.6 or Stratum 2=LDA: 2.6&lt;=DAS28-ESR&lt;3.2).</method_desc>
            <param_type>Difference in proportions</param_type>
            <param_value>8.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.43</ci_lower_limit>
            <ci_upper_limit>15.20</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Moderate Response: DAS28-ESR Week 44</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.035</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Stratified by geographic region and disease status at randomization (Stratum 1=Remission: DAS28-ESR&lt;2.6 or Stratum 2=LDA: 2.6&lt;=DAS28-ESR&lt;3.2).</method_desc>
            <param_type>Difference in proportions</param_type>
            <param_value>11.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>4.69</ci_lower_limit>
            <ci_upper_limit>18.72</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Moderate Response: DAS28-ESR Week 44</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.030</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Stratified by geographic region and disease status at randomization (Stratum 1=Remission: DAS28-ESR&lt;2.6 or Stratum 2=LDA: 2.6&lt;=DAS28-ESR&lt;3.2).</method_desc>
            <param_type>Difference in proportions</param_type>
            <param_value>10.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>4.20</ci_lower_limit>
            <ci_upper_limit>17.06</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Moderate Response: DAS28-ESR Week 52</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.048</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Stratified by geographic region and disease status at randomization (Stratum 1=Remission: DAS28-ESR&lt;2.6 or Stratum 2=LDA: 2.6&lt;=DAS28-ESR&lt;3.2).</method_desc>
            <param_type>Difference in proportions</param_type>
            <param_value>11.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>4.15</ci_lower_limit>
            <ci_upper_limit>18.06</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Moderate Response: DAS28-CRP Week 52</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.016</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Stratified by geographic region and disease status at randomization (Stratum 1=Remission: DAS28-ESR&lt;2.6 or Stratum 2=LDA: 2.6&lt;=DAS28-ESR&lt;3.2).</method_desc>
            <param_type>Difference in proportions</param_type>
            <param_value>11.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>4.92</ci_lower_limit>
            <ci_upper_limit>17.58</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving LDA or Remission Based on Clinical Disease Activity Index (CDAI) and Simplified Disease Activity Index (SDAI) at Each Visit During Period 1.</title>
        <description>SDAI and CDAI are defined as:
1) SDAI = DAS28 prorated Swollen Joint Count (0-28) + DAS28 prorated Tender Joint Count (0-28) + Physician Global Assessment of arthritis (0-10) + Subject Global Assessment of arthritis (0-10) + hs CRP (in mg/dL) in Period 1. 2) CDAI = DAS28 prorated Swollen Joint Count (0-28) + DAS28 prorated Tender Joint Count (0 28) + Physician Global Assessment of arthritis (0-10) + Subject Global Assessment of arthritis (0-10) in Period 1.</description>
        <time_frame>Baseline, Weeks 4, 8, 16 and 24</time_frame>
        <population>The FAS for Period 1 (Open Label FAS) included all randomized participants who had at least one dose of open label study drug during Period 1 (ie, ETN or MTX).</population>
        <group_list>
          <group group_id="O1">
            <title>Open-Label Treatment</title>
            <description>Participants in open-label treatment received ETN 50 mg QW with MTX (with or without other DMARDs).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving LDA or Remission Based on Clinical Disease Activity Index (CDAI) and Simplified Disease Activity Index (SDAI) at Each Visit During Period 1.</title>
          <description>SDAI and CDAI are defined as:
1) SDAI = DAS28 prorated Swollen Joint Count (0-28) + DAS28 prorated Tender Joint Count (0-28) + Physician Global Assessment of arthritis (0-10) + Subject Global Assessment of arthritis (0-10) + hs CRP (in mg/dL) in Period 1. 2) CDAI = DAS28 prorated Swollen Joint Count (0-28) + DAS28 prorated Tender Joint Count (0 28) + Physician Global Assessment of arthritis (0-10) + Subject Global Assessment of arthritis (0-10) in Period 1.</description>
          <population>The FAS for Period 1 (Open Label FAS) included all randomized participants who had at least one dose of open label study drug during Period 1 (ie, ETN or MTX).</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="478"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>CDAI: LDA Baseline (N= 478)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CDAI: LDA Week 4 (N= 473)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CDAI: LDA Week 8 (N= 473)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CDAI: LDA Week 16 (N= 473)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CDAI: LDA Week 24 (N= 473)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CDAI: Remission: Baseline (N= 478)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CDAI: Remission: Week 4 (N= 473)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CDAI: Remission: Week 8 (N= 473)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CDAI: Remission: Week 16 (N= 473)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CDAI: Remission: Week 24 (N= 473)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SDAI: LDA: Baseline (N= 478)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SDAI: LDA: Week 4 (N= 465)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SDAI: LDA: Week 8 (N= 471)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SDAI: LDA: Week 16 (N= 472)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SDAI: LDA: Week 24 (N= 472)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SDAI: Remission: Baseline (N= 478)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SDAI: Remission: Week 4 (N= 465)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SDAI: Remission: Week 8 (N= 471)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SDAI: Remission: Week 16 (N= 472)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SDAI: Remission: Week 24 (N= 472)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving LDA or Remission Based on CDAI and SDAI at Each Visit During Period 2.</title>
        <description>SDAI and CDAI are defined as:
1) SDAI = DAS28 prorated Swollen Joint Count (0-28) + DAS28 prorated Tender Joint Count (0-28) + Physician Global Assessment of arthritis (0-10) + Subject Global Assessment of arthritis (0-10) + hs CRP (in mg/dL) in Period 2. 2) CDAI = DAS28 prorated Swollen Joint Count (0-28) + DAS28 prorated Tender Joint Count (0 28) + Physician Global Assessment of arthritis (0-10) + Subject Global Assessment of arthritis (0-10) in Period 2.</description>
        <time_frame>Baseline, Weeks 24, 28, 36, 44 and 52</time_frame>
        <population>The FAS included all randomized participants who met the period 2 DAS28-ESR inclusion criteria, had at least one dose of study drug during Period 2 (ie, ETN, MTX or PBO) and had at least one valid efficacy (DAS28-ESR) evaluation after randomization</population>
        <group_list>
          <group group_id="O1">
            <title>Etanercept</title>
            <description>Participants were randomized to receive ETN 50 mg QW with MTX (with or without other DMARDs).</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants were randomized to receive PBO 50 mg QW + MTX (with or without DMARDs).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving LDA or Remission Based on CDAI and SDAI at Each Visit During Period 2.</title>
          <description>SDAI and CDAI are defined as:
1) SDAI = DAS28 prorated Swollen Joint Count (0-28) + DAS28 prorated Tender Joint Count (0-28) + Physician Global Assessment of arthritis (0-10) + Subject Global Assessment of arthritis (0-10) + hs CRP (in mg/dL) in Period 2. 2) CDAI = DAS28 prorated Swollen Joint Count (0-28) + DAS28 prorated Tender Joint Count (0 28) + Physician Global Assessment of arthritis (0-10) + Subject Global Assessment of arthritis (0-10) in Period 2.</description>
          <population>The FAS included all randomized participants who met the period 2 DAS28-ESR inclusion criteria, had at least one dose of study drug during Period 2 (ie, ETN, MTX or PBO) and had at least one valid efficacy (DAS28-ESR) evaluation after randomization</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="163"/>
                <count group_id="O2" value="168"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>CDAI: LDA Baseline (N= 163, 168)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CDAI: LDA Week 24 (N= 163, 168)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93.9"/>
                    <measurement group_id="O2" value="90.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CDAI: LDA Week 28 (N= 163, 168)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.1"/>
                    <measurement group_id="O2" value="57.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CDAI: LDA Week 36 (N= 163, 168)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.2"/>
                    <measurement group_id="O2" value="47.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CDAI: LDA Week 44 (N= 163, 168)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.6"/>
                    <measurement group_id="O2" value="43.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CDAI: LDA Week 52 (N= 163, 168)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.9"/>
                    <measurement group_id="O2" value="42.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CDAI: Remission: Baseline (N= 163, 168)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CDAI: Remission: Week 24 (N= 163, 168)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.6"/>
                    <measurement group_id="O2" value="14.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CDAI: Remission: Week 28 (N= 163, 168)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.7"/>
                    <measurement group_id="O2" value="14.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CDAI: Remission: Week 36 (N= 163, 168)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.9"/>
                    <measurement group_id="O2" value="12.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CDAI: Remission: Week 44 (N= 163, 168)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.1"/>
                    <measurement group_id="O2" value="12.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CDAI: Remission: Week 52 (N= 163, 168)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.9"/>
                    <measurement group_id="O2" value="11.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SDAI: LDA: Baseline (N= 163, 168)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SDAI: LDA: Week 24 (N= 163, 168)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90.2"/>
                    <measurement group_id="O2" value="86.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SDAI: LDA: Week 28 (N= 160, 166)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.1"/>
                    <measurement group_id="O2" value="55.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SDAI: LDA: Week 36 (N= 162, 167)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.8"/>
                    <measurement group_id="O2" value="42.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SDAI: LDA: Week 44 (N= 162, 167)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.8"/>
                    <measurement group_id="O2" value="42.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SDAI: LDA: Week 52 (N= 162, 167)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.8"/>
                    <measurement group_id="O2" value="37.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SDAI: Remission: Baseline (N= 163, 168)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SDAI: Remission: Week 24 (N= 163, 168)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.9"/>
                    <measurement group_id="O2" value="17.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SDAI: Remission: Week 28 (N= 160, 166)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.3"/>
                    <measurement group_id="O2" value="16.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SDAI: Remission: Week 36 (N= 162, 167)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.8"/>
                    <measurement group_id="O2" value="12.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SDAI: Remission: Week 44 (N= 162, 167)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.2"/>
                    <measurement group_id="O2" value="13.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SDAI: Remission: Week 52 (N= 162, 167)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.3"/>
                    <measurement group_id="O2" value="13.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>CDAI: LDA Baseline</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.358</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Stratified by geographic region and disease status at randomization (Stratum 1=Remission: DAS28-ESR&lt;2.6 or Stratum 2=LDA: 2.6&lt;=DAS28-ESR&lt;3.2).</method_desc>
            <param_type>Difference in proportions</param_type>
            <param_value>0.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.59</ci_lower_limit>
            <ci_upper_limit>1.81</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>CDAI: LDA: Week 24</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.341</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Stratified by geographic region and disease status at randomization (Stratum 1=Remission: DAS28-ESR&lt;2.6 or Stratum 2=LDA: 2.6&lt;=DAS28-ESR&lt;3.2).</method_desc>
            <param_type>Difference in proportions</param_type>
            <param_value>3.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.38</ci_lower_limit>
            <ci_upper_limit>9.16</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>CDAI: LDA: Week 28</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.004</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Stratified by geographic region and disease status at randomization (Stratum 1=Remission: DAS28-ESR&lt;2.6 or Stratum 2=LDA: 2.6&lt;=DAS28-ESR&lt;3.2).</method_desc>
            <param_type>Difference in proportions</param_type>
            <param_value>18.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>8.40</ci_lower_limit>
            <ci_upper_limit>28.27</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>CDAI: LDA: Week 36</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Stratified by geographic region and disease status at randomization (Stratum 1=Remission: DAS28-ESR&lt;2.6 or Stratum 2=LDA: 2.6&lt;=DAS28-ESR&lt;3.2).</method_desc>
            <param_type>Difference in proportions</param_type>
            <param_value>24.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>13.88</ci_lower_limit>
            <ci_upper_limit>34.40</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>CDAI: LDA: Week 44</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Stratified by geographic region and disease status at randomization (Stratum 1=Remission: DAS28-ESR&lt;2.6 or Stratum 2=LDA: 2.6&lt;=DAS28-ESR&lt;3.2).</method_desc>
            <param_type>Difference in proportions</param_type>
            <param_value>27.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>16.85</ci_lower_limit>
            <ci_upper_limit>37.35</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>CDAI: LDA: Week 52</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Stratified by geographic region and disease status at randomization (Stratum 1=Remission: DAS28-ESR&lt;2.6 or Stratum 2=LDA: 2.6&lt;=DAS28-ESR&lt;3.2).</method_desc>
            <param_type>Difference in proportions</param_type>
            <param_value>24.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>13.61</ci_lower_limit>
            <ci_upper_limit>34.42</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>CDAI: Remission: Week 24</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.774</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Stratified by geographic region and disease status at randomization (Stratum 1=Remission: DAS28-ESR&lt;2.6 or Stratum 2=LDA: 2.6&lt;=DAS28-ESR&lt;3.2).</method_desc>
            <param_type>Difference in proportions</param_type>
            <param_value>2.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.50</ci_lower_limit>
            <ci_upper_limit>10.06</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>CDAI: Remission: Week 28</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.645</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Stratified by geographic region and disease status at randomization (Stratum 1=Remission: DAS28-ESR&lt;2.6 or Stratum 2=LDA: 2.6&lt;=DAS28-ESR&lt;3.2).</method_desc>
            <param_type>Difference in proportions</param_type>
            <param_value>0.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-7.15</ci_lower_limit>
            <ci_upper_limit>8.03</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>CDAI: Remission: Week 36</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.080</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Stratified by geographic region and disease status at randomization (Stratum 1=Remission: DAS28-ESR&lt;2.6 or Stratum 2=LDA: 2.6&lt;=DAS28-ESR&lt;3.2).</method_desc>
            <param_type>Difference in proportions</param_type>
            <param_value>8.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.36</ci_lower_limit>
            <ci_upper_limit>16.35</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>CDAI: Remission: Week 44</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.025</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Stratified by geographic region and disease status at randomization (Stratum 1=Remission: DAS28-ESR&lt;2.6 or Stratum 2=LDA: 2.6&lt;=DAS28-ESR&lt;3.2).</method_desc>
            <param_type>Difference in proportions</param_type>
            <param_value>9.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.49</ci_lower_limit>
            <ci_upper_limit>17.68</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>CDAI: Remission: Week 52</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.088</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Stratified by geographic region and disease status at randomization (Stratum 1=Remission: DAS28-ESR&lt;2.6 or Stratum 2=LDA: 2.6&lt;=DAS28-ESR&lt;3.2).</method_desc>
            <param_type>Difference in proportions</param_type>
            <param_value>9.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.02</ci_lower_limit>
            <ci_upper_limit>16.88</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>SDAI: LDA: Baseline</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.358</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Stratified by geographic region and disease status at randomization (Stratum 1=Remission: DAS28-ESR&lt;2.6 or Stratum 2=LDA: 2.6&lt;=DAS28-ESR&lt;3.2).</method_desc>
            <param_type>Difference in proportions</param_type>
            <param_value>0.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.59</ci_lower_limit>
            <ci_upper_limit>1.81</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>SDAI: LDA: Week 24</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.258</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Stratified by geographic region and disease status at randomization (Stratum 1=Remission: DAS28-ESR&lt;2.6 or Stratum 2=LDA: 2.6&lt;=DAS28-ESR&lt;3.2).</method_desc>
            <param_type>Difference in proportions</param_type>
            <param_value>3.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.57</ci_lower_limit>
            <ci_upper_limit>10.13</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>SDAI: LDA: Week 28</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.005</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Stratified by geographic region and disease status at randomization (Stratum 1=Remission: DAS28-ESR&lt;2.6 or Stratum 2=LDA: 2.6&lt;=DAS28-ESR&lt;3.2).</method_desc>
            <param_type>Difference in proportions</param_type>
            <param_value>17.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>7.49</ci_lower_limit>
            <ci_upper_limit>27.92</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>SDAI: LDA: Week 36</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Stratified by geographic region and disease status at randomization (Stratum 1=Remission: DAS28-ESR&lt;2.6 or Stratum 2=LDA: 2.6&lt;=DAS28-ESR&lt;3.2).</method_desc>
            <param_type>Difference in proportions</param_type>
            <param_value>27.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>16.93</ci_lower_limit>
            <ci_upper_limit>37.55</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>SDAI: LDA: Week 44</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Stratified by geographic region and disease status at randomization (Stratum 1=Remission: DAS28-ESR&lt;2.6 or Stratum 2=LDA: 2.6&lt;=DAS28-ESR&lt;3.2).</method_desc>
            <param_type>Difference in proportions</param_type>
            <param_value>32.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>21.83</ci_lower_limit>
            <ci_upper_limit>42.23</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>SDAI: LDA: Week 52</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Stratified by geographic region and disease status at randomization (Stratum 1=Remission: DAS28-ESR&lt;2.6 or Stratum 2=LDA: 2.6&lt;=DAS28-ESR&lt;3.2).</method_desc>
            <param_type>Difference in proportions</param_type>
            <param_value>28.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>18.00</ci_lower_limit>
            <ci_upper_limit>38.69</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>SDAI: Remission: Week 24</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.672</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Stratified by geographic region and disease status at randomization (Stratum 1=Remission: DAS28-ESR&lt;2.6 or Stratum 2=LDA: 2.6&lt;=DAS28-ESR&lt;3.2).</method_desc>
            <param_type>Difference in proportions</param_type>
            <param_value>3.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.51</ci_lower_limit>
            <ci_upper_limit>11.51</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>SDAI: Remission: Week 28</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.556</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Stratified by geographic region and disease status at randomization (Stratum 1=Remission: DAS28-ESR&lt;2.6 or Stratum 2=LDA: 2.6&lt;=DAS28-ESR&lt;3.2).</method_desc>
            <param_type>Difference in proportions</param_type>
            <param_value>-0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-8.03</ci_lower_limit>
            <ci_upper_limit>8.00</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>SDAI: Remission: Week 36</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.022</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Stratified by geographic region and disease status at randomization (Stratum 1=Remission: DAS28-ESR&lt;2.6 or Stratum 2=LDA: 2.6&lt;=DAS28-ESR&lt;3.2).</method_desc>
            <param_type>Difference in proportions</param_type>
            <param_value>10.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.07</ci_lower_limit>
            <ci_upper_limit>18.45</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>SDAI: Remission: Week 44</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.047</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Stratified by geographic region and disease status at randomization (Stratum 1=Remission: DAS28-ESR&lt;2.6 or Stratum 2=LDA: 2.6&lt;=DAS28-ESR&lt;3.2).</method_desc>
            <param_type>Difference in proportions</param_type>
            <param_value>9.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.85</ci_lower_limit>
            <ci_upper_limit>17.25</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>SDAI: Remission: Week 52</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.031</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Stratified by geographic region and disease status at randomization (Stratum 1=Remission: DAS28-ESR&lt;2.6 or Stratum 2=LDA: 2.6&lt;=DAS28-ESR&lt;3.2).</method_desc>
            <param_type>Difference in proportions</param_type>
            <param_value>12.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>3.70</ci_lower_limit>
            <ci_upper_limit>20.57</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change of CDAI and SDAI at Each Visit During Period 1.</title>
        <description>SDAI and CDAI are defined as:
1) SDAI = DAS28 prorated Swollen Joint Count (0-28) + DAS28 prorated Tender Joint Count (0-28) + Physician Global Assessment of arthritis (0-10) + Subject Global Assessment of arthritis (0-10) + hs CRP (in mg/dL) in Period 1. 2) CDAI = DAS28 prorated Swollen Joint Count (0-28) + DAS28 prorated Tender Joint Count (0 28) + Physician Global Assessment of arthritis (0-10) + Subject Global Assessment of arthritis (0-10) in Period 1.</description>
        <time_frame>Baseline, Weeks 4, 8, 16 and 24</time_frame>
        <population>The FAS for Period 1 (Open Label FAS) included all randomized participants who had at least one dose of open label study drug during Period 1 (ie, ETN or MTX).</population>
        <group_list>
          <group group_id="O1">
            <title>Open-Label Treatment</title>
            <description>Participants in open-label treatment received ETN 50 mg QW with MTX (with or without other DMARDs).</description>
          </group>
        </group_list>
        <measure>
          <title>Change of CDAI and SDAI at Each Visit During Period 1.</title>
          <description>SDAI and CDAI are defined as:
1) SDAI = DAS28 prorated Swollen Joint Count (0-28) + DAS28 prorated Tender Joint Count (0-28) + Physician Global Assessment of arthritis (0-10) + Subject Global Assessment of arthritis (0-10) + hs CRP (in mg/dL) in Period 1. 2) CDAI = DAS28 prorated Swollen Joint Count (0-28) + DAS28 prorated Tender Joint Count (0 28) + Physician Global Assessment of arthritis (0-10) + Subject Global Assessment of arthritis (0-10) in Period 1.</description>
          <population>The FAS for Period 1 (Open Label FAS) included all randomized participants who had at least one dose of open label study drug during Period 1 (ie, ETN or MTX).</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="478"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>CDAI Week 4 (N= 473)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-16.78" spread="11.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CDAI Week 8 (N= 473)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-21.69" spread="12.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CDAI Week 16 (N= 473)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-25.77" spread="13.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CDAI Week 24 (N= 473)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-29.25" spread="13.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SDAI Week 4 (N= 465)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-18.19" spread="12.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SDAI Week 8 (N= 471)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-23.06" spread="12.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SDAI Week 16 (N= 472)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-27.17" spread="13.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SDAI Week 24 (N= 472)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-30.56" spread="14.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change of CDAI and SDAI at Each Visit During Period 2</title>
        <description>SDAI and CDAI are defined as:
1) SDAI = DAS28 prorated Swollen Joint Count (0-28) + DAS28 prorated Tender Joint Count (0-28) + Physician Global Assessment of arthritis (0-10) + Subject Global Assessment of arthritis (0-10) + hs CRP (in mg/dL) in Period 2. 2) CDAI = DAS28 prorated Swollen Joint Count (0-28) + DAS28 prorated Tender Joint Count (0 28) + Physician Global Assessment of arthritis (0-10) + Subject Global Assessment of arthritis (0-10) in Period 2.</description>
        <time_frame>Baseline, Weeks 24, 28, 36, 44 and 52</time_frame>
        <population>The FAS included all randomized participants who met the period 2 DAS28-ESR inclusion criteria, had at least one dose of study drug during Period 2 (ie, ETN, MTX or PBO) and had at least one valid efficacy (DAS28-ESR) evaluation after randomization.</population>
        <group_list>
          <group group_id="O1">
            <title>Etanercept</title>
            <description>Participants were randomized to receive ETN 50 mg QW with MTX (with or without other DMARDs).</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants were randomized to receive PBO 50 mg QW + MTX (with or without DMARDs).</description>
          </group>
        </group_list>
        <measure>
          <title>Change of CDAI and SDAI at Each Visit During Period 2</title>
          <description>SDAI and CDAI are defined as:
1) SDAI = DAS28 prorated Swollen Joint Count (0-28) + DAS28 prorated Tender Joint Count (0-28) + Physician Global Assessment of arthritis (0-10) + Subject Global Assessment of arthritis (0-10) + hs CRP (in mg/dL) in Period 2. 2) CDAI = DAS28 prorated Swollen Joint Count (0-28) + DAS28 prorated Tender Joint Count (0 28) + Physician Global Assessment of arthritis (0-10) + Subject Global Assessment of arthritis (0-10) in Period 2.</description>
          <population>The FAS included all randomized participants who met the period 2 DAS28-ESR inclusion criteria, had at least one dose of study drug during Period 2 (ie, ETN, MTX or PBO) and had at least one valid efficacy (DAS28-ESR) evaluation after randomization.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="163"/>
                <count group_id="O2" value="168"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>CDAI: Week 24 (N= 163, 168)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-32.11" spread="12.06"/>
                    <measurement group_id="O2" value="-32.23" spread="12.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CDAI: Week 28 (N= 163, 168)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-29.62" spread="13.10"/>
                    <measurement group_id="O2" value="-26.49" spread="15.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CDAI: Week 36 (N= 163, 168)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-28.71" spread="13.56"/>
                    <measurement group_id="O2" value="-24.33" spread="16.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CDAI: Week 44 (N= 163, 168)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-28.63" spread="13.58"/>
                    <measurement group_id="O2" value="-23.81" spread="16.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CDAI: Week 52 (N= 163, 168)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-28.30" spread="13.61"/>
                    <measurement group_id="O2" value="-23.52" spread="15.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SDAI: Week 24 (N= 163, 168)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-33.61" spread="12.07"/>
                    <measurement group_id="O2" value="-33.68" spread="13.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SDAI: Week 28 (N= 160, 166)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-31.07" spread="13.58"/>
                    <measurement group_id="O2" value="-27.58" spread="16.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SDAI: Week 36 (N= 162, 167)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-30.20" spread="14.05"/>
                    <measurement group_id="O2" value="-25.44" spread="17.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SDAI: Week 44 (N= 162, 167)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-30.21" spread="14.14"/>
                    <measurement group_id="O2" value="-24.85" spread="17.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SDAI: Week 52 (N= 162, 167)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-29.86" spread="14.03"/>
                    <measurement group_id="O2" value="-24.57" spread="16.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>CDAI: Week 28</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.049</p_value>
            <method>ANCOVA</method>
            <method_desc>Stratified by geographic region and disease status at randomization (Stratum 1=Remission: DAS28-ESR&lt;2.6 or Stratum 2=LDA: 2.6&lt;=DAS28-ESR&lt;3.2).</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-2.10</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.19</ci_lower_limit>
            <ci_upper_limit>-0.01</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>CDAI: Week 36</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.005</p_value>
            <method>ANCOVA</method>
            <method_desc>Stratified by geographic region and disease status at randomization (Stratum 1=Remission: DAS28-ESR&lt;2.6 or Stratum 2=LDA: 2.6&lt;=DAS28-ESR&lt;3.2).</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-3.38</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.72</ci_lower_limit>
            <ci_upper_limit>-1.05</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>CDAI: Week 44</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <method_desc>Stratified by geographic region and disease status at randomization (Stratum 1=Remission: DAS28-ESR&lt;2.6 or Stratum 2=LDA: 2.6&lt;=DAS28-ESR&lt;3.2).</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-4.02</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.37</ci_lower_limit>
            <ci_upper_limit>-1.67</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>CDAI: Week 52</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <method_desc>Stratified by geographic region and disease status at randomization (Stratum 1=Remission: DAS28-ESR&lt;2.6 or Stratum 2=LDA: 2.6&lt;=DAS28-ESR&lt;3.2).</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-4.02</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.36</ci_lower_limit>
            <ci_upper_limit>-1.68</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>SDAI: Week 28</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.047</p_value>
            <method>ANCOVA</method>
            <method_desc>Stratified by geographic region and disease status at randomization (Stratum 1=Remission: DAS28-ESR&lt;2.6 or Stratum 2=LDA: 2.6&lt;=DAS28-ESR&lt;3.2).</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-2.22</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.40</ci_lower_limit>
            <ci_upper_limit>-0.03</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>SDAI: Week 36</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.004</p_value>
            <method>ANCOVA</method>
            <method_desc>Stratified by geographic region and disease status at randomization (Stratum 1=Remission: DAS28-ESR&lt;2.6 or Stratum 2=LDA: 2.6&lt;=DAS28-ESR&lt;3.2).</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-3.54</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.97</ci_lower_limit>
            <ci_upper_limit>-1.12</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>SDAI: Week 44</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <method_desc>Stratified by geographic region and disease status at randomization (Stratum 1=Remission: DAS28-ESR&lt;2.6 or Stratum 2=LDA: 2.6&lt;=DAS28-ESR&lt;3.2).</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-4.33</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.78</ci_lower_limit>
            <ci_upper_limit>-1.88</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>SDAI: Week 52</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <method_desc>Stratified by geographic region and disease status at randomization (Stratum 1=Remission: DAS28-ESR&lt;2.6 or Stratum 2=LDA: 2.6&lt;=DAS28-ESR&lt;3.2).</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-4.27</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.70</ci_lower_limit>
            <ci_upper_limit>-1.84</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving American College of Rheumatology (ACR) ACR20, ACR50, ACR70 and ACR90 (by 66/68 Joint Counts) During Period 1 at Each Visit.</title>
        <description>A 66 swollen and 68 tender joint count was used for calculating ACR responses. The ACR’s definition for calculating improvement in RA (ACR20) was calculated as a 20% improvement in tender and swollen joint counts and 20% improvement in 3 of the 5 remaining ACR core set measures: subject and physician global assessments of arthritis, pain, disability, and an acute phase reactant. Similarly, ACR50, ACR70 and ACR90 were calculated with the respective percent improvement. This efficacy measurement was made at every study visit.</description>
        <time_frame>Baseline, Weeks 4, 8, 16 and 24</time_frame>
        <population>The FAS for Period 1 (Open Label FAS) included all randomized participants who had at least one dose of open label study drug during Period 1 (ie, ETN or MTX).</population>
        <group_list>
          <group group_id="O1">
            <title>Open-Label Treatment</title>
            <description>Participants in open-label treatment received ETN 50 mg QW with MTX (with or without other DMARDs).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving American College of Rheumatology (ACR) ACR20, ACR50, ACR70 and ACR90 (by 66/68 Joint Counts) During Period 1 at Each Visit.</title>
          <description>A 66 swollen and 68 tender joint count was used for calculating ACR responses. The ACR’s definition for calculating improvement in RA (ACR20) was calculated as a 20% improvement in tender and swollen joint counts and 20% improvement in 3 of the 5 remaining ACR core set measures: subject and physician global assessments of arthritis, pain, disability, and an acute phase reactant. Similarly, ACR50, ACR70 and ACR90 were calculated with the respective percent improvement. This efficacy measurement was made at every study visit.</description>
          <population>The FAS for Period 1 (Open Label FAS) included all randomized participants who had at least one dose of open label study drug during Period 1 (ie, ETN or MTX).</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="478"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>ACR 20: Week 4 (N= 469)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.6" spread="1.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACR 20: Week 8 (N= 469)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.1" spread="1.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACR 20: Week 16 (N= 469)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83.6" spread="1.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACR 20: Week 24 (N= 469)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87.8" spread="1.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACR 50: Week 4 (N= 469)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.8" spread="1.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACR 50: Week 8 (N= 469)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.8" spread="1.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACR 50: Week 16 (N= 469)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.2" spread="1.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACR 50: Week 24 (N= 469)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.5" spread="1.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACR 70: Week 4 (N= 469)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACR 70: Week 8 (N= 469)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACR 70: Week 16 (N= 469)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACR 70: Week 24 (N= 469)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACR 90: Week 4 (N= 469)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACR 90: Week 8 (N= 469)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACR 90: Week 16 (N= 469)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACR 90: Week 24 (N= 469)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving ACR20, ACR50, ACR70 and ACR90 (by 66/68 Joint Counts) During Period 2 at Each Visit.</title>
        <description>A 66 swollen and 68 tender joint count was used for calculating ACR responses. The ACR’s definition for calculating improvement in RA (ACR20) was calculated as a 20% improvement in tender and swollen joint counts and 20% improvement in 3 of the 5 remaining ACR core set measures: subject and physician global assessments of arthritis, pain, disability, and an acute phase reactant. Similarly, ACR50, ACR70 and ACR90 were calculated with the respective percent improvement. This efficacy measurement was made at every study visit.</description>
        <time_frame>Baseline, Weeks 24, 28, 36, 44 and 52</time_frame>
        <population>The FAS included all randomized participants who met the period 2 DAS28-ESR inclusion criteria, had at least one dose of study drug during Period 2 (ie, ETN, MTX or PBO) and had at least one valid efficacy (DAS28-ESR) evaluation after randomization.</population>
        <group_list>
          <group group_id="O1">
            <title>Etanercept</title>
            <description>Participants were randomized to receive ETN 50 mg QW with MTX (with or without other DMARDs).</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants were randomized to receive PBO 50 mg QW + MTX (with or without DMARDs).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving ACR20, ACR50, ACR70 and ACR90 (by 66/68 Joint Counts) During Period 2 at Each Visit.</title>
          <description>A 66 swollen and 68 tender joint count was used for calculating ACR responses. The ACR’s definition for calculating improvement in RA (ACR20) was calculated as a 20% improvement in tender and swollen joint counts and 20% improvement in 3 of the 5 remaining ACR core set measures: subject and physician global assessments of arthritis, pain, disability, and an acute phase reactant. Similarly, ACR50, ACR70 and ACR90 were calculated with the respective percent improvement. This efficacy measurement was made at every study visit.</description>
          <population>The FAS included all randomized participants who met the period 2 DAS28-ESR inclusion criteria, had at least one dose of study drug during Period 2 (ie, ETN, MTX or PBO) and had at least one valid efficacy (DAS28-ESR) evaluation after randomization.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="163"/>
                <count group_id="O2" value="168"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>ACR 20: Week 24 (N= 161, 168)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.3"/>
                    <measurement group_id="O2" value="96.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACR 20: Week 28 (N= 161, 168)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91.3"/>
                    <measurement group_id="O2" value="81.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACR 20: Week 36 (N= 161, 168)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88.2"/>
                    <measurement group_id="O2" value="76.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACR 20: Week 44 (N= 161, 168)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86.3"/>
                    <measurement group_id="O2" value="76.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACR 20: Week 52 (N= 161, 168)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87.0"/>
                    <measurement group_id="O2" value="76.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACR 50: Week 24 (N= 161, 168)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88.2"/>
                    <measurement group_id="O2" value="85.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACR 50: Week 28 (N= 161, 168)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.2"/>
                    <measurement group_id="O2" value="63.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACR 50: Week 36 (N= 161, 168)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.9"/>
                    <measurement group_id="O2" value="51.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACR 50: Week 44 (N= 161, 168)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.6"/>
                    <measurement group_id="O2" value="50.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACR 50: Week 52 (N= 161, 168)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.3"/>
                    <measurement group_id="O2" value="50.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACR 70: Week 24 (N= 161, 168)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.7"/>
                    <measurement group_id="O2" value="52.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACR 70: Week 28 (N= 161, 168)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.0"/>
                    <measurement group_id="O2" value="33.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACR 70: Week 36 (N= 161, 168)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.7"/>
                    <measurement group_id="O2" value="27.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACR 70: Week 44 (N= 161, 168)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.5"/>
                    <measurement group_id="O2" value="25.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACR 70: Week 52 (N= 161, 168)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.0"/>
                    <measurement group_id="O2" value="25.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACR 90: Week 24 (N= 161, 168)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.1"/>
                    <measurement group_id="O2" value="8.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACR 90: Week 28 (N= 161, 168)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.7"/>
                    <measurement group_id="O2" value="5.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACR 90: Week 36 (N= 161, 168)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.8"/>
                    <measurement group_id="O2" value="5.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACR 90: Week 44 (N= 161, 168)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.3"/>
                    <measurement group_id="O2" value="4.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACR 90: Week 52 (N= 161, 168)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.0"/>
                    <measurement group_id="O2" value="7.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>ACR 20: Week 24</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.742</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Stratified by geographic region and disease status at randomization (Stratum 1=Remission: DAS28-ESR&lt;2.6 or Stratum 2=LDA: 2.6&lt;=DAS28-ESR&lt;3.2).</method_desc>
            <param_type>Difference in proportions</param_type>
            <param_value>-0.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.21</ci_lower_limit>
            <ci_upper_limit>3.90</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>ACR 20: Week 28</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.143</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Stratified by geographic region and disease status at randomization (Stratum 1=Remission: DAS28-ESR&lt;2.6 or Stratum 2=LDA: 2.6&lt;=DAS28-ESR&lt;3.2).</method_desc>
            <param_type>Difference in proportions</param_type>
            <param_value>9.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.45</ci_lower_limit>
            <ci_upper_limit>17.06</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>ACR 20: Week 36</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.111</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Stratified by geographic region and disease status at randomization (Stratum 1=Remission: DAS28-ESR&lt;2.6 or Stratum 2=LDA: 2.6&lt;=DAS28-ESR&lt;3.2).</method_desc>
            <param_type>Difference in proportions</param_type>
            <param_value>11.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>3.31</ci_lower_limit>
            <ci_upper_limit>19.51</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>ACR 20: Week 44</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.175</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Stratified by geographic region and disease status at randomization (Stratum 1=Remission: DAS28-ESR&lt;2.6 or Stratum 2=LDA: 2.6&lt;=DAS28-ESR&lt;3.2).</method_desc>
            <param_type>Difference in proportions</param_type>
            <param_value>10.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.80</ci_lower_limit>
            <ci_upper_limit>18.49</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>ACR 20: Week 52</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.088</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Stratified by geographic region and disease status at randomization (Stratum 1=Remission: DAS28-ESR&lt;2.6 or Stratum 2=LDA: 2.6&lt;=DAS28-ESR&lt;3.2).</method_desc>
            <param_type>Difference in proportions</param_type>
            <param_value>10.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.49</ci_lower_limit>
            <ci_upper_limit>19.05</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>ACR 50: Week 24</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.584</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Stratified by geographic region and disease status at randomization (Stratum 1=Remission: DAS28-ESR&lt;2.6 or Stratum 2=LDA: 2.6&lt;=DAS28-ESR&lt;3.2).</method_desc>
            <param_type>Difference in proportions</param_type>
            <param_value>2.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.78</ci_lower_limit>
            <ci_upper_limit>9.75</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>ACR 50: Week 28</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.226</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Stratified by geographic region and disease status at randomization (Stratum 1=Remission: DAS28-ESR&lt;2.6 or Stratum 2=LDA: 2.6&lt;=DAS28-ESR&lt;3.2).</method_desc>
            <param_type>Difference in proportions</param_type>
            <param_value>11.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.59</ci_lower_limit>
            <ci_upper_limit>21.34</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>ACR 50: Week 36</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.012</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Stratified by geographic region and disease status at randomization (Stratum 1=Remission: DAS28-ESR&lt;2.6 or Stratum 2=LDA: 2.6&lt;=DAS28-ESR&lt;3.2).</method_desc>
            <param_type>Difference in proportions</param_type>
            <param_value>17.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>6.76</ci_lower_limit>
            <ci_upper_limit>27.56</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>ACR 50: Week 44</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.006</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Stratified by geographic region and disease status at randomization (Stratum 1=Remission: DAS28-ESR&lt;2.6 or Stratum 2=LDA: 2.6&lt;=DAS28-ESR&lt;3.2).</method_desc>
            <param_type>Difference in proportions</param_type>
            <param_value>19.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>8.59</ci_lower_limit>
            <ci_upper_limit>29.35</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>ACR 50: Week 52</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.014</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Stratified by geographic region and disease status at randomization (Stratum 1=Remission: DAS28-ESR&lt;2.6 or Stratum 2=LDA: 2.6&lt;=DAS28-ESR&lt;3.2).</method_desc>
            <param_type>Difference in Proportions</param_type>
            <param_value>17.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>7.30</ci_lower_limit>
            <ci_upper_limit>28.16</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>ACR 70: Week 24</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.702</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Stratified by geographic region and disease status at randomization (Stratum 1=Remission: DAS28-ESR&lt;2.6 or Stratum 2=LDA: 2.6&lt;=DAS28-ESR&lt;3.2).</method_desc>
            <param_type>Difference in Proportions</param_type>
            <param_value>-2.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-13.49</ci_lower_limit>
            <ci_upper_limit>8.11</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>ACR 70: Week 28</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.378</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Stratified by geographic region and disease status at randomization (Stratum 1=Remission: DAS28-ESR&lt;2.6 or Stratum 2=LDA: 2.6&lt;=DAS28-ESR&lt;3.2).</method_desc>
            <param_type>Difference in proportions</param_type>
            <param_value>7.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.37</ci_lower_limit>
            <ci_upper_limit>17.50</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>ACR 70: Week 36</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.004</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Stratified by geographic region and disease status at randomization (Stratum 1=Remission: DAS28-ESR&lt;2.6 or Stratum 2=LDA: 2.6&lt;=DAS28-ESR&lt;3.2).</method_desc>
            <param_type>Difference in proportions</param_type>
            <param_value>17.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>7.12</ci_lower_limit>
            <ci_upper_limit>27.56</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>ACR 70: Week 44</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Stratified by geographic region and disease status at randomization (Stratum 1=Remission: DAS28-ESR&lt;2.6 or Stratum 2=LDA: 2.6&lt;=DAS28-ESR&lt;3.2).</method_desc>
            <param_type>Difference in proportions</param_type>
            <param_value>18.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>8.40</ci_lower_limit>
            <ci_upper_limit>28.55</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>ACR 70: Week 52</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.005</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Stratified by geographic region and disease status at randomization (Stratum 1=Remission: DAS28-ESR&lt;2.6 or Stratum 2=LDA: 2.6&lt;=DAS28-ESR&lt;3.2).</method_desc>
            <param_type>Difference in proportions</param_type>
            <param_value>16.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>5.96</ci_lower_limit>
            <ci_upper_limit>26.02</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>ACR 90: Week 24</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.921</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Stratified by geographic region and disease status at randomization (Stratum 1=Remission: DAS28-ESR&lt;2.6 or Stratum 2=LDA: 2.6&lt;=DAS28-ESR&lt;3.2).</method_desc>
            <param_type>Difference in proportions</param_type>
            <param_value>-0.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.19</ci_lower_limit>
            <ci_upper_limit>5.67</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>ACR 90: Week 28</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.410</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Stratified by geographic region and disease status at randomization (Stratum 1=Remission: DAS28-ESR&lt;2.6 or Stratum 2=LDA: 2.6&lt;=DAS28-ESR&lt;3.2).</method_desc>
            <param_type>Difference in proportions</param_type>
            <param_value>3.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.19</ci_lower_limit>
            <ci_upper_limit>8.86</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>ACR 90: Week 36</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.073</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Stratified by geographic region and disease status at randomization (Stratum 1=Remission: DAS28-ESR&lt;2.6 or Stratum 2=LDA: 2.6&lt;=DAS28-ESR&lt;3.2).</method_desc>
            <param_type>Difference in proportions</param_type>
            <param_value>6.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.41</ci_lower_limit>
            <ci_upper_limit>12.48</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>ACR 90: Week 44</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.219</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Stratified by geographic region and disease status at randomization (Stratum 1=Remission: DAS28-ESR&lt;2.6 or Stratum 2=LDA: 2.6&lt;=DAS28-ESR&lt;3.2).</method_desc>
            <param_type>Difference in proportions</param_type>
            <param_value>4.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.97</ci_lower_limit>
            <ci_upper_limit>10.08</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>ACR 90: Week 52</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.196</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Stratified by geographic region and disease status at randomization (Stratum 1=Remission: DAS28-ESR&lt;2.6 or Stratum 2=LDA: 2.6&lt;=DAS28-ESR&lt;3.2).</method_desc>
            <param_type>Difference in proportions</param_type>
            <param_value>5.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.60</ci_lower_limit>
            <ci_upper_limit>12.40</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in the Tender and Swollen Joint Counts at Each Visit During Period 1 (Using 28 Joint Count as Well as 66/68 Joint Counts).</title>
        <description>A total of 66 swollen and 68 tender joints were assessed for tenderness/pain and swelling by the same qualified personnel (when possible) at each visit. For ACR responses, a 66/68 joint count was used. For DAS28-ESR, Simplified Disease Activity Index (SDAI), and Clinical Disease Activity Index (CDAI) calculations, the 28 joint count was used, which included: shoulders, elbows, wrists, metacarpophalangeal (MCP) joints, proximal interphalangeal (PIP) joints, and knees.</description>
        <time_frame>Baseline, Weeks 4, 8, 16 and 24</time_frame>
        <population>The FAS for Period 1 (Open Label FAS) included all randomized participants who had at least one dose of open label study drug during Period 1 (ie, ETN or MTX).</population>
        <group_list>
          <group group_id="O1">
            <title>Open-Label Treatment</title>
            <description>Participants in open-label treatment received ETN 50 mg QW with MTX (with or without other DMARDs).</description>
          </group>
        </group_list>
        <measure>
          <title>Change in the Tender and Swollen Joint Counts at Each Visit During Period 1 (Using 28 Joint Count as Well as 66/68 Joint Counts).</title>
          <description>A total of 66 swollen and 68 tender joints were assessed for tenderness/pain and swelling by the same qualified personnel (when possible) at each visit. For ACR responses, a 66/68 joint count was used. For DAS28-ESR, Simplified Disease Activity Index (SDAI), and Clinical Disease Activity Index (CDAI) calculations, the 28 joint count was used, which included: shoulders, elbows, wrists, metacarpophalangeal (MCP) joints, proximal interphalangeal (PIP) joints, and knees.</description>
          <population>The FAS for Period 1 (Open Label FAS) included all randomized participants who had at least one dose of open label study drug during Period 1 (ie, ETN or MTX).</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="478"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>28 Tender Joint Count: Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.49" spread="6.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>28 Tender Joint Count: Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.59" spread="6.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>28 Tender Joint Count: Week 16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.12" spread="6.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>28 Tender Joint Count: Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.50" spread="6.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>28 Swollen Joint Count: Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.52" spread="5.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>28 Swollen Joint Count: Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.04" spread="5.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>28 Swollen Joint Count: Week 16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.21" spread="5.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>28 Swollen Joint Count: Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.01" spread="5.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>68 Tender Joint Count: Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.71" spread="10.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>68 Tender Joint Count: Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13.02" spread="10.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>68 Tender Joint Count: Week 16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-15.21" spread="11.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>68 Tender Joint Count: Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-17.41" spread="12.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>68 Swollen Joint Count: Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.12" spread="6.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>68 Swollen Joint Count: Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.03" spread="7.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>68 Swollen Joint Count: Week 16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.49" spread="7.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>68 Swollen Joint Count: Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.53" spread="8.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in the Tender and Swollen Joint Counts at Each Visit During Period 2 (Using 28 Joint Count as Well as 66/68 Joint Counts).</title>
        <description>A total of 66 swollen and 68 tender joints were assessed for tenderness/pain and swelling by the same qualified personnel (when possible) at each visit. For ACR responses, a 66/68 joint count was used. For DAS28-ESR, Simplified Disease Activity Index (SDAI), and Clinical Disease Activity Index (CDAI) calculations, the 28 joint count was used, which included: shoulders, elbows, wrists, metacarpophalangeal (MCP) joints, proximal interphalangeal (PIP) joints, and knees.</description>
        <time_frame>Baseline, Weeks 24, 28, 36, 44 and 52</time_frame>
        <population>The FAS included all randomized participants who met the period 2 DAS28-ESR inclusion criteria, had at least one dose of study drug during Period 2 (ie, ETN, MTX or PBO) and had at least one valid efficacy (DAS28-ESR) evaluation after randomization.</population>
        <group_list>
          <group group_id="O1">
            <title>Etanercept</title>
            <description>Participants were randomized to receive ETN 50 mg QW with MTX (with or without other DMARDs).</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants were randomized to receive PBO 50 mg QW + MTX (with or without DMARDs).</description>
          </group>
        </group_list>
        <measure>
          <title>Change in the Tender and Swollen Joint Counts at Each Visit During Period 2 (Using 28 Joint Count as Well as 66/68 Joint Counts).</title>
          <description>A total of 66 swollen and 68 tender joints were assessed for tenderness/pain and swelling by the same qualified personnel (when possible) at each visit. For ACR responses, a 66/68 joint count was used. For DAS28-ESR, Simplified Disease Activity Index (SDAI), and Clinical Disease Activity Index (CDAI) calculations, the 28 joint count was used, which included: shoulders, elbows, wrists, metacarpophalangeal (MCP) joints, proximal interphalangeal (PIP) joints, and knees.</description>
          <population>The FAS included all randomized participants who met the period 2 DAS28-ESR inclusion criteria, had at least one dose of study drug during Period 2 (ie, ETN, MTX or PBO) and had at least one valid efficacy (DAS28-ESR) evaluation after randomization.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="163"/>
                <count group_id="O2" value="168"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>28 Tender Joint Count: Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12.65" spread="6.25"/>
                    <measurement group_id="O2" value="-12.35" spread="6.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>28 Tender Joint Count: Week 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.69" spread="6.74"/>
                    <measurement group_id="O2" value="-10.08" spread="7.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>28 Tender Joint Count: Week 36</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.22" spread="6.91"/>
                    <measurement group_id="O2" value="-9.23" spread="8.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>28 Tender Joint Count: Week 44</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.19" spread="6.82"/>
                    <measurement group_id="O2" value="-8.97" spread="8.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>28 Tender Joint Count: Week 52</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.03" spread="6.81"/>
                    <measurement group_id="O2" value="-8.78" spread="7.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>28 Swollen Joint Count: Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.78" spread="5.16"/>
                    <measurement group_id="O2" value="-9.98" spread="5.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>28 Swollen Joint Count: Week 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.97" spread="5.27"/>
                    <measurement group_id="O2" value="-8.70" spread="5.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>28 Swollen Joint Count: Week 36</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.64" spread="5.51"/>
                    <measurement group_id="O2" value="-8.16" spread="6.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>28 Swollen Joint Count: Week 44</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.71" spread="5.52"/>
                    <measurement group_id="O2" value="-8.03" spread="6.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>28 Swollen Joint Count: Week 52</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.59" spread="5.42"/>
                    <measurement group_id="O2" value="-7.98" spread="6.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>68 Tender Joint Count: Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-18.31" spread="12.13"/>
                    <measurement group_id="O2" value="-18.19" spread="12.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>68 Tender Joint Count: Week 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-17.02" spread="12.48"/>
                    <measurement group_id="O2" value="-15.20" spread="13.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>68 Tender Joint Count: Week 36</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-17.27" spread="12.55"/>
                    <measurement group_id="O2" value="-17.13" spread="14.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>68 Tender Joint Count: Week 44</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-18.67" spread="12.90"/>
                    <measurement group_id="O2" value="-18.82" spread="14.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>68 Tender Joint Count: Week 52</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-17.88" spread="13.21"/>
                    <measurement group_id="O2" value="-17.61" spread="12.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>68 Swollen Joint Count: Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12.09" spread="7.76"/>
                    <measurement group_id="O2" value="-12.40" spread="8.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>68 Swollen Joint Count: Week 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.23" spread="7.77"/>
                    <measurement group_id="O2" value="-10.81" spread="8.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>68 Swollen Joint Count: Week 36</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.26" spread="8.05"/>
                    <measurement group_id="O2" value="-10.67" spread="8.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>68 Swollen Joint Count: Week 44</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12.00" spread="8.03"/>
                    <measurement group_id="O2" value="-11.63" spread="8.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>68 Swollen Joint Count: Week 52</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.98" spread="8.17"/>
                    <measurement group_id="O2" value="-11.89" spread="8.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>28 Tender Joint Count: Week 28</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.062</p_value>
            <method>ANCOVA</method>
            <method_desc>Stratified by geographic region and disease status at randomization (Stratum 1=Remission: DAS28-ESR&lt;2.6 or Stratum 2=LDA: 2.6&lt;=DAS28-ESR&lt;3.2).</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.90</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.84</ci_lower_limit>
            <ci_upper_limit>0.05</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>28 Tender Joint Count: Week 36</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.015</p_value>
            <method>ANCOVA</method>
            <method_desc>Stratified by geographic region and disease status at randomization (Stratum 1=Remission: DAS28-ESR&lt;2.6 or Stratum 2=LDA: 2.6&lt;=DAS28-ESR&lt;3.2).</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1.34</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.41</ci_lower_limit>
            <ci_upper_limit>-0.27</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>28 Tender Joint Count: Week 44</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.003</p_value>
            <method>ANCOVA</method>
            <method_desc>Stratified by geographic region and disease status at randomization (Stratum 1=Remission: DAS28-ESR&lt;2.6 or Stratum 2=LDA: 2.6&lt;=DAS28-ESR&lt;3.2).</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1.65</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.72</ci_lower_limit>
            <ci_upper_limit>-0.57</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>28 Tender Joint Count: Week 52</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.002</p_value>
            <method>ANCOVA</method>
            <method_desc>Stratified by geographic region and disease status at randomization (Stratum 1=Remission: DAS28-ESR&lt;2.6 or Stratum 2=LDA: 2.6&lt;=DAS28-ESR&lt;3.2).</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1.75</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.85</ci_lower_limit>
            <ci_upper_limit>-0.66</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>28 Swollen Joint Count: Week 28</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.680</p_value>
            <method>ANCOVA</method>
            <method_desc>Stratified by geographic region and disease status at randomization (Stratum 1=Remission: DAS28-ESR&lt;2.6 or Stratum 2=LDA: 2.6&lt;=DAS28-ESR&lt;3.2).</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.13</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.77</ci_lower_limit>
            <ci_upper_limit>0.50</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>28 Swollen Joint Count: Week 36</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.437</p_value>
            <method>ANCOVA</method>
            <method_desc>Stratified by geographic region and disease status at randomization (Stratum 1=Remission: DAS28-ESR&lt;2.6 or Stratum 2=LDA: 2.6&lt;=DAS28-ESR&lt;3.2).</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.29</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.04</ci_lower_limit>
            <ci_upper_limit>0.45</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>28 Swollen Joint Count: Week 44</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.131</p_value>
            <method>ANCOVA</method>
            <method_desc>Stratified by geographic region and disease status at randomization (Stratum 1=Remission: DAS28-ESR&lt;2.6 or Stratum 2=LDA: 2.6&lt;=DAS28-ESR&lt;3.2).</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.57</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.31</ci_lower_limit>
            <ci_upper_limit>0.17</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>28 Swollen Joint Count: Week 52</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.199</p_value>
            <method>ANCOVA</method>
            <method_desc>Stratified by geographic region and disease status at randomization (Stratum 1=Remission: DAS28-ESR&lt;2.6 or Stratum 2=LDA: 2.6&lt;=DAS28-ESR&lt;3.2).</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.48</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.22</ci_lower_limit>
            <ci_upper_limit>0.25</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>68 Tender Joint Count: Week 28</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.115</p_value>
            <method>ANCOVA</method>
            <method_desc>Stratified by geographic region and disease status at randomization (Stratum 1=Remission: DAS28-ESR&lt;2.6 or Stratum 2=LDA: 2.6&lt;=DAS28-ESR&lt;3.2).</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1.16</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.60</ci_lower_limit>
            <ci_upper_limit>0.28</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>68 Tender Joint Count: Week 36</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.017</p_value>
            <method>ANCOVA</method>
            <method_desc>Stratified by geographic region and disease status at randomization (Stratum 1=Remission: DAS28-ESR&lt;2.6 or Stratum 2=LDA: 2.6&lt;=DAS28-ESR&lt;3.2).</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1.88</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.42</ci_lower_limit>
            <ci_upper_limit>-0.35</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>68 Tender Joint Count: Week 44</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.004</p_value>
            <method>ANCOVA</method>
            <method_desc>Stratified by geographic region and disease status at randomization (Stratum 1=Remission: DAS28-ESR&lt;2.6 or Stratum 2=LDA: 2.6&lt;=DAS28-ESR&lt;3.2).</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-2.34</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.91</ci_lower_limit>
            <ci_upper_limit>-0.76</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>68 Tender Joint Count: Week 52</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.002</p_value>
            <method>ANCOVA</method>
            <method_desc>Stratified by geographic region and disease status at randomization (Stratum 1=Remission: DAS28-ESR&lt;2.6 or Stratum 2=LDA: 2.6&lt;=DAS28-ESR&lt;3.2).</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-2.58</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.19</ci_lower_limit>
            <ci_upper_limit>-0.97</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>68 Swollen Joint Count: Week 28</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.368</p_value>
            <method>ANCOVA</method>
            <method_desc>Stratified by geographic region and disease status at randomization (Stratum 1=Remission: DAS28-ESR&lt;2.6 or Stratum 2=LDA: 2.6&lt;=DAS28-ESR&lt;3.2).</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.36</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.13</ci_lower_limit>
            <ci_upper_limit>0.42</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>68 Swollen Joint Count: Week 36</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.208</p_value>
            <method>ANCOVA</method>
            <method_desc>Stratified by geographic region and disease status at randomization (Stratum 1=Remission: DAS28-ESR&lt;2.6 or Stratum 2=LDA: 2.6&lt;=DAS28-ESR&lt;3.2).</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.57</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.46</ci_lower_limit>
            <ci_upper_limit>0.32</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>68 Swollen Joint Count: Week 44</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.064</p_value>
            <method>ANCOVA</method>
            <method_desc>Stratified by geographic region and disease status at randomization (Stratum 1=Remission: DAS28-ESR&lt;2.6 or Stratum 2=LDA: 2.6&lt;=DAS28-ESR&lt;3.2).</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.84</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.73</ci_lower_limit>
            <ci_upper_limit>0.05</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>68 Swollen Joint Count: Week 52</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.081</p_value>
            <method>ANCOVA</method>
            <method_desc>Stratified by geographic region and disease status at randomization (Stratum 1=Remission: DAS28-ESR&lt;2.6 or Stratum 2=LDA: 2.6&lt;=DAS28-ESR&lt;3.2).</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.78</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.66</ci_lower_limit>
            <ci_upper_limit>0.10</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in the Physician Global Assessment of Arthritis at Each Visit During Period 1</title>
        <description>The investigator estimated the subject’s overall disease activity over the last 2 to 3 days (independent of the Subject Global Assessment of arthritis) using a scale between 0 (no disease activity) and 10 (extreme disease activity) and marking one number with an ‘X’.</description>
        <time_frame>Baseline, Weeks 4, 8, 16 and 24</time_frame>
        <population>The FAS for Period 1 (Open Label FAS) included all randomized participants who had at least one dose of open label study drug during Period 1 (ie, ETN or MTX).</population>
        <group_list>
          <group group_id="O1">
            <title>Open-Label Treatment</title>
            <description>Participants in open-label treatment received ETN 50 mg QW with MTX (with or without other DMARDs).</description>
          </group>
        </group_list>
        <measure>
          <title>Change in the Physician Global Assessment of Arthritis at Each Visit During Period 1</title>
          <description>The investigator estimated the subject’s overall disease activity over the last 2 to 3 days (independent of the Subject Global Assessment of arthritis) using a scale between 0 (no disease activity) and 10 (extreme disease activity) and marking one number with an ‘X’.</description>
          <population>The FAS for Period 1 (Open Label FAS) included all randomized participants who had at least one dose of open label study drug during Period 1 (ie, ETN or MTX).</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="478"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4 (N= 473)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.60" spread="1.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8 (N= 473)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.46" spread="1.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16 (N= 473)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.12" spread="1.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24 (N= 473)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.79" spread="2.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in the Physician Global Assessment of Arthritis at Each Visit During Period 2</title>
        <description>The investigator estimated the subject’s overall disease activity over the last 2 to 3 days (independent of the Subject Global Assessment of arthritis) using a scale between 0 (no disease activity) and 10 (extreme disease activity) and marking one number with an ‘X’.</description>
        <time_frame>Baseline, Weeks 24, 28, 36, 44 and 52</time_frame>
        <population>The FAS included all randomized participants who met the period 2 DAS28-ESR inclusion criteria, had at least one dose of study drug during Period 2 (ie, ETN, MTX or PBO) and had at least one valid efficacy (DAS28-ESR) evaluation after randomization.</population>
        <group_list>
          <group group_id="O1">
            <title>Etanercept</title>
            <description>Participants were randomized to receive ETN 50 mg QW with MTX (with or without other DMARDs).</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants were randomized to receive PBO 50 mg QW + MTX (with or without DMARDs).</description>
          </group>
        </group_list>
        <measure>
          <title>Change in the Physician Global Assessment of Arthritis at Each Visit During Period 2</title>
          <description>The investigator estimated the subject’s overall disease activity over the last 2 to 3 days (independent of the Subject Global Assessment of arthritis) using a scale between 0 (no disease activity) and 10 (extreme disease activity) and marking one number with an ‘X’.</description>
          <population>The FAS included all randomized participants who met the period 2 DAS28-ESR inclusion criteria, had at least one dose of study drug during Period 2 (ie, ETN, MTX or PBO) and had at least one valid efficacy (DAS28-ESR) evaluation after randomization.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="163"/>
                <count group_id="O2" value="168"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.28" spread="1.56"/>
                    <measurement group_id="O2" value="-5.26" spread="1.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.93" spread="1.78"/>
                    <measurement group_id="O2" value="-4.23" spread="2.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.83" spread="1.86"/>
                    <measurement group_id="O2" value="-3.89" spread="2.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 44</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.82" spread="2.02"/>
                    <measurement group_id="O2" value="-3.79" spread="2.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.77" spread="2.03"/>
                    <measurement group_id="O2" value="-3.74" spread="2.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 28</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.005</p_value>
            <method>ANCOVA</method>
            <method_desc>Stratified by geographic region and disease status at randomization (Stratum 1=Remission: DAS28-ESR&lt;2.6 or Stratum 2=LDA: 2.6&lt;=DAS28-ESR&lt;3.2).</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.53</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.90</ci_lower_limit>
            <ci_upper_limit>-0.16</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 36</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <method_desc>Stratified by geographic region and disease status at randomization (Stratum 1=Remission: DAS28-ESR&lt;2.6 or Stratum 2=LDA: 2.6&lt;=DAS28-ESR&lt;3.2).</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.78</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.18</ci_lower_limit>
            <ci_upper_limit>-0.38</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 44</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <method_desc>Stratified by geographic region and disease status at randomization (Stratum 1=Remission: DAS28-ESR&lt;2.6 or Stratum 2=LDA: 2.6&lt;=DAS28-ESR&lt;3.2).</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.94</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.35</ci_lower_limit>
            <ci_upper_limit>-0.54</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 52</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <method_desc>Stratified by geographic region and disease status at randomization (Stratum 1=Remission: DAS28-ESR&lt;2.6 or Stratum 2=LDA: 2.6&lt;=DAS28-ESR&lt;3.2).</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.93</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.33</ci_lower_limit>
            <ci_upper_limit>-0.53</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in the Subject Global Assessment of Arthritis in Period 1</title>
        <description>Subjects assessed their overall disease activity over the last 2 to 3 days using a scale between 0 (no disease activity) and 10 (extreme disease activity), which corresponded to the magnitude of their pain) and marked one number with an ‘X’.</description>
        <time_frame>Baseline, Weeks 4, 8, 16 and 24</time_frame>
        <population>The FAS for Period 1 (Open Label FAS) included all randomized participants who had at least one dose of open label study drug during Period 1 (ie, ETN or MTX).</population>
        <group_list>
          <group group_id="O1">
            <title>Open-Label Treatment</title>
            <description>Participants in open-label treatment received ETN 50 mg QW with MTX (with or without other DMARDs).</description>
          </group>
        </group_list>
        <measure>
          <title>Change in the Subject Global Assessment of Arthritis in Period 1</title>
          <description>Subjects assessed their overall disease activity over the last 2 to 3 days using a scale between 0 (no disease activity) and 10 (extreme disease activity), which corresponded to the magnitude of their pain) and marked one number with an ‘X’.</description>
          <population>The FAS for Period 1 (Open Label FAS) included all randomized participants who had at least one dose of open label study drug during Period 1 (ie, ETN or MTX).</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="478"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4 (N= 473)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.18" spread="2.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8 (N= 473)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.60" spread="2.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16 (N= 473)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.32" spread="2.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24 (N= 473)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.97" spread="2.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in the Subject Global Assessment of Arthritis in Period 2</title>
        <description>Subjects assessed their overall disease activity over the last 2 to 3 days using a scale between 0 (no disease activity) and 10 (extreme disease activity), which corresponded to the magnitude of their pain) and marked one number with an ‘X’.</description>
        <time_frame>Baseline, Weeks 24, 28, 36, 44 and 52</time_frame>
        <population>The FAS included all randomized participants who met the period 2 DAS28-ESR inclusion criteria, had at least one dose of study drug during Period 2 (ie, ETN, MTX or PBO) and had at least one valid efficacy (DAS28-ESR) evaluation after randomization.</population>
        <group_list>
          <group group_id="O1">
            <title>Etanercept</title>
            <description>Participants were randomized to receive ETN 50 mg QW with MTX (with or without other DMARDs).</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants were randomized to receive PBO 50 mg QW + MTX (with or without DMARDs).</description>
          </group>
        </group_list>
        <measure>
          <title>Change in the Subject Global Assessment of Arthritis in Period 2</title>
          <description>Subjects assessed their overall disease activity over the last 2 to 3 days using a scale between 0 (no disease activity) and 10 (extreme disease activity), which corresponded to the magnitude of their pain) and marked one number with an ‘X’.</description>
          <population>The FAS included all randomized participants who met the period 2 DAS28-ESR inclusion criteria, had at least one dose of study drug during Period 2 (ie, ETN, MTX or PBO) and had at least one valid efficacy (DAS28-ESR) evaluation after randomization.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="163"/>
                <count group_id="O2" value="168"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.39" spread="2.43"/>
                    <measurement group_id="O2" value="-4.64" spread="2.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.03" spread="2.70"/>
                    <measurement group_id="O2" value="-3.48" spread="2.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.02" spread="2.71"/>
                    <measurement group_id="O2" value="-3.05" spread="2.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 44</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.92" spread="2.79"/>
                    <measurement group_id="O2" value="-3.02" spread="2.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.91" spread="2.84"/>
                    <measurement group_id="O2" value="-3.02" spread="2.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 28</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.048</p_value>
            <method>ANCOVA</method>
            <method_desc>Stratified by geographic region and disease status at randomization (Stratum 1=Remission: DAS28-ESR&lt;2.6 or Stratum 2=LDA: 2.6&lt;=DAS28-ESR&lt;3.2).</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.50</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.00</ci_lower_limit>
            <ci_upper_limit>-0.01</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 36</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <method_desc>Stratified by geographic region and disease status at randomization (Stratum 1=Remission: DAS28-ESR&lt;2.6 or Stratum 2=LDA: 2.6&lt;=DAS28-ESR&lt;3.2).</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.93</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.44</ci_lower_limit>
            <ci_upper_limit>-0.43</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 44</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.001</p_value>
            <method>ANCOVA</method>
            <method_desc>Stratified by geographic region and disease status at randomization (Stratum 1=Remission: DAS28-ESR&lt;2.6 or Stratum 2=LDA: 2.6&lt;=DAS28-ESR&lt;3.2).</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.83</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.33</ci_lower_limit>
            <ci_upper_limit>-0.33</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 52</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.002</p_value>
            <method>ANCOVA</method>
            <method_desc>Stratified by geographic region and disease status at randomization (Stratum 1=Remission: DAS28-ESR&lt;2.6 or Stratum 2=LDA: 2.6&lt;=DAS28-ESR&lt;3.2).</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.82</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.33</ci_lower_limit>
            <ci_upper_limit>-0.31</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Morning Stiffness (Measured in Minutes) at Each Visit During Period 1</title>
        <description>Morning stiffness was defined as stiffness in and around the joints, lasting at least 1 hour before maximal improvement. Participants assessed their overall disease activity over the last 2 to 3 days using a scale between 0 (no disease activity) and 10 (extreme disease activity), which corresponded to the magnitude of their pain) and marked one number with an ‘X’.</description>
        <time_frame>Baseline, Weeks 4, 8, 16 and 24</time_frame>
        <population>The FAS for Period 1 (Open Label FAS) included all randomized participants who had at least one dose of open label study drug during Period 1 (ie, ETN or MTX).</population>
        <group_list>
          <group group_id="O1">
            <title>Open-Label Treatment</title>
            <description>Participants in open-label treatment received ETN 50 mg QW with MTX (with or without other DMARDs).</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Morning Stiffness (Measured in Minutes) at Each Visit During Period 1</title>
          <description>Morning stiffness was defined as stiffness in and around the joints, lasting at least 1 hour before maximal improvement. Participants assessed their overall disease activity over the last 2 to 3 days using a scale between 0 (no disease activity) and 10 (extreme disease activity), which corresponded to the magnitude of their pain) and marked one number with an ‘X’.</description>
          <population>The FAS for Period 1 (Open Label FAS) included all randomized participants who had at least one dose of open label study drug during Period 1 (ie, ETN or MTX).</population>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="478"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4 (N= 467)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-78.56" spread="143.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8 (N= 467)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-90.58" spread="147.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16 (N= 467)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-102.25" spread="158.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24 (N= 467)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-109.32" spread="183.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Morning Stiffness (Measured in Minutes) at Each Visit During Period 2</title>
        <description>Morning stiffness was defined as stiffness in and around the joints, lasting at least 1 hour before maximal improvement. Participants assessed their overall disease activity over the last 2 to 3 days using a scale between 0 (no disease activity) and 10 (extreme disease activity), which corresponded to the magnitude of their pain) and marked one number with an ‘X’.</description>
        <time_frame>Baseline, Weeks 24, 28, 36, 44 and 52</time_frame>
        <population>The FAS included all randomized participants who met the period 2 DAS28-ESR inclusion criteria, had at least one dose of study drug during Period 2 (ie, ETN, MTX or PBO) and had at least one valid efficacy (DAS28-ESR) evaluation after randomization.</population>
        <group_list>
          <group group_id="O1">
            <title>Etanercept</title>
            <description>Participants were randomized to receive ETN 50 mg QW with MTX (with or without other DMARDs).</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants were randomized to receive PBO 50 mg QW + MTX (with or without DMARDs).</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Morning Stiffness (Measured in Minutes) at Each Visit During Period 2</title>
          <description>Morning stiffness was defined as stiffness in and around the joints, lasting at least 1 hour before maximal improvement. Participants assessed their overall disease activity over the last 2 to 3 days using a scale between 0 (no disease activity) and 10 (extreme disease activity), which corresponded to the magnitude of their pain) and marked one number with an ‘X’.</description>
          <population>The FAS included all randomized participants who met the period 2 DAS28-ESR inclusion criteria, had at least one dose of study drug during Period 2 (ie, ETN, MTX or PBO) and had at least one valid efficacy (DAS28-ESR) evaluation after randomization.</population>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="163"/>
                <count group_id="O2" value="168"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 24 (N= 163, 166)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-118.30" spread="171.15"/>
                    <measurement group_id="O2" value="-121.93" spread="186.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 28 (N= 163, 166)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-134.42" spread="224.70"/>
                    <measurement group_id="O2" value="-109.57" spread="163.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36 (N= 163, 166)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-132.05" spread="224.86"/>
                    <measurement group_id="O2" value="-104.40" spread="164.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 44 (N= 163, 166)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-129.86" spread="223.78"/>
                    <measurement group_id="O2" value="-103.14" spread="162.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52 (N= 163, 166)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-129.49" spread="223.68"/>
                    <measurement group_id="O2" value="-100.31" spread="153.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 28</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.033</p_value>
            <method>ANCOVA</method>
            <method_desc>Stratified by geographic region and disease status at randomization (Stratum 1=Remission: DAS28-ESR&lt;2.6 or Stratum 2=LDA: 2.6&lt;=DAS28-ESR&lt;3.2).</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-14.11</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-27.07</ci_lower_limit>
            <ci_upper_limit>-1.16</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 36</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.013</p_value>
            <method>ANCOVA</method>
            <method_desc>Stratified by geographic region and disease status at randomization (Stratum 1=Remission: DAS28-ESR&lt;2.6 or Stratum 2=LDA: 2.6&lt;=DAS28-ESR&lt;3.2).</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-17.04</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-30.39</ci_lower_limit>
            <ci_upper_limit>-3.68</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 44</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.019</p_value>
            <method>ANCOVA</method>
            <method_desc>Stratified by geographic region and disease status at randomization (Stratum 1=Remission: DAS28-ESR&lt;2.6 or Stratum 2=LDA: 2.6&lt;=DAS28-ESR&lt;3.2).</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-16.54</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-30.35</ci_lower_limit>
            <ci_upper_limit>-2.73</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 52</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.007</p_value>
            <method>ANCOVA</method>
            <method_desc>Stratified by geographic region and disease status at randomization (Stratum 1=Remission: DAS28-ESR&lt;2.6 or Stratum 2=LDA: 2.6&lt;=DAS28-ESR&lt;3.2).</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-19.66</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-33.78</ci_lower_limit>
            <ci_upper_limit>-5.54</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in the Subject General Health Visual Analog Scale (VAS) and Pain VAS at Each Visit During Period 1</title>
        <description>Participants were asked to answer the question “In general how would you rate your health over the last 2 3 weeks?” by marking a vertical line at the appropriate position through the 100 mm VAS. The length on the line was measured from the left (in mm). For Pain VAS, participants assessed the severity of their arthritis pain during the last 2 to 3 days using a 100 mm VAS by marking a vertical line at the appropriate position on the scale between 0 (no pain) and 100 (most severe pain), which corresponded to the magnitude of their pain.</description>
        <time_frame>Baseline, Weeks 4, 8, 16 and 24</time_frame>
        <population>The FAS for Period 1 (Open Label FAS) included all randomized participants who had at least one dose of open label study drug during Period 1 (ie, ETN or MTX).</population>
        <group_list>
          <group group_id="O1">
            <title>Open-Label Treatment</title>
            <description>Participants in open-label treatment received ETN 50 mg QW with MTX (with or without other DMARDs).</description>
          </group>
        </group_list>
        <measure>
          <title>Change in the Subject General Health Visual Analog Scale (VAS) and Pain VAS at Each Visit During Period 1</title>
          <description>Participants were asked to answer the question “In general how would you rate your health over the last 2 3 weeks?” by marking a vertical line at the appropriate position through the 100 mm VAS. The length on the line was measured from the left (in mm). For Pain VAS, participants assessed the severity of their arthritis pain during the last 2 to 3 days using a 100 mm VAS by marking a vertical line at the appropriate position on the scale between 0 (no pain) and 100 (most severe pain), which corresponded to the magnitude of their pain.</description>
          <population>The FAS for Period 1 (Open Label FAS) included all randomized participants who had at least one dose of open label study drug during Period 1 (ie, ETN or MTX).</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="478"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>General Health VAS: Week 4 (N= 473)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-20.20" spread="22.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>General Health VAS: Week 8 (N= 473)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-25.17" spread="24.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>General Health VAS: Week 16 (N= 473)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-32.54" spread="24.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>General Health VAS: Week 24 (N= 473)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-40.67" spread="26.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain VAS: Week 4 (N= 473)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-24.07" spread="22.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain VAS: Week 8 (N= 473)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-28.55" spread="24.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain VAS: Week 16 (N= 473)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-35.20" spread="24.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain VAS: Week 24 (N= 473)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-42.49" spread="26.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in the Subject General Health VAS and Pain VAS at Each Visit During Period 2</title>
        <description>Participants were asked to answer the question “In general how would you rate your health over the last 2-3 weeks?” by marking a vertical line at the appropriate position through the 100 mm VAS. The length on the line was measured from the left (in mm). For Pain VAS, participants assessed the severity of their arthritis pain during the last 2 to 3 days using a 100 mm VAS by marking a vertical line at the appropriate position on the scale between 0 (no pain) and 100 (most severe pain), which corresponded to the magnitude of their pain.</description>
        <time_frame>Baseline, Weeks 24, 28, 36, 44 and 52</time_frame>
        <population>The FAS included all randomized participants who met the period 2 DAS28-ESR inclusion criteria, had at least one dose of study drug during Period 2 (ie, ETN, MTX or PBO) and had at least one valid efficacy (DAS28-ESR) evaluation after randomization.</population>
        <group_list>
          <group group_id="O1">
            <title>Etanercept</title>
            <description>Participants were randomized to receive ETN 50 mg QW with MTX (with or without other DMARDs).</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants were randomized to receive PBO 50 mg QW + MTX (with or without DMARDs).</description>
          </group>
        </group_list>
        <measure>
          <title>Change in the Subject General Health VAS and Pain VAS at Each Visit During Period 2</title>
          <description>Participants were asked to answer the question “In general how would you rate your health over the last 2-3 weeks?” by marking a vertical line at the appropriate position through the 100 mm VAS. The length on the line was measured from the left (in mm). For Pain VAS, participants assessed the severity of their arthritis pain during the last 2 to 3 days using a 100 mm VAS by marking a vertical line at the appropriate position on the scale between 0 (no pain) and 100 (most severe pain), which corresponded to the magnitude of their pain.</description>
          <population>The FAS included all randomized participants who met the period 2 DAS28-ESR inclusion criteria, had at least one dose of study drug during Period 2 (ie, ETN, MTX or PBO) and had at least one valid efficacy (DAS28-ESR) evaluation after randomization.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="163"/>
                <count group_id="O2" value="168"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>General Health VAS: Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-46.66" spread="24.72"/>
                    <measurement group_id="O2" value="-47.53" spread="20.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>General Health VAS: Week 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-41.31" spread="27.01"/>
                    <measurement group_id="O2" value="-34.95" spread="28.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>General Health VAS: Week 36</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-39.84" spread="26.56"/>
                    <measurement group_id="O2" value="-30.74" spread="29.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>General Health VAS: Week 44</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-39.82" spread="27.61"/>
                    <measurement group_id="O2" value="-30.10" spread="29.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>General Health VAS: Week 52</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-39.81" spread="28.16"/>
                    <measurement group_id="O2" value="-29.67" spread="29.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain VAS: Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-46.61" spread="24.33"/>
                    <measurement group_id="O2" value="-49.69" spread="20.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain VAS: Week 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-43.30" spread="26.34"/>
                    <measurement group_id="O2" value="-38.17" spread="29.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain VAS: Week 36</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-41.42" spread="27.01"/>
                    <measurement group_id="O2" value="-34.00" spread="30.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain VAS: Week 44</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-41.21" spread="28.01"/>
                    <measurement group_id="O2" value="-33.07" spread="29.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain VAS: Week 52</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-40.95" spread="28.61"/>
                    <measurement group_id="O2" value="-32.91" spread="29.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>General Health VAS: Week 28</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.078</p_value>
            <method>ANCOVA</method>
            <method_desc>Stratified by geographic region and disease status at randomization (Stratum 1=Remission: DAS28-ESR&lt;2.6 or Stratum 2=LDA: 2.6&lt;=DAS28-ESR&lt;3.2).</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-4.21</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-8.91</ci_lower_limit>
            <ci_upper_limit>0.48</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>General Health VAS: Week 36</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.003</p_value>
            <method>ANCOVA</method>
            <method_desc>Stratified by geographic region and disease status at randomization (Stratum 1=Remission: DAS28-ESR&lt;2.6 or Stratum 2=LDA: 2.6&lt;=DAS28-ESR&lt;3.2).</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-7.54</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-12.49</ci_lower_limit>
            <ci_upper_limit>-2.59</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>General Health VAS: Week 44</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.001</p_value>
            <method>ANCOVA</method>
            <method_desc>Stratified by geographic region and disease status at randomization (Stratum 1=Remission: DAS28-ESR&lt;2.6 or Stratum 2=LDA: 2.6&lt;=DAS28-ESR&lt;3.2).</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-8.19</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-13.20</ci_lower_limit>
            <ci_upper_limit>-3.18</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>General Health VAS: Week 52</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <method_desc>Stratified by geographic region and disease status at randomization (Stratum 1=Remission: DAS28-ESR&lt;2.6 or Stratum 2=LDA: 2.6&lt;=DAS28-ESR&lt;3.2).</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-8.60</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-13.64</ci_lower_limit>
            <ci_upper_limit>-3.55</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Pain VAS: Week 28</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.017</p_value>
            <method>ANCOVA</method>
            <method_desc>Stratified by geographic region and disease status at randomization (Stratum 1=Remission: DAS28-ESR&lt;2.6 or Stratum 2=LDA: 2.6&lt;=DAS28-ESR&lt;3.2).</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-5.91</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-10.75</ci_lower_limit>
            <ci_upper_limit>-1.06</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Pain VAS: Week 36</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.001</p_value>
            <method>ANCOVA</method>
            <method_desc>Stratified by geographic region and disease status at randomization (Stratum 1=Remission: DAS28-ESR&lt;2.6 or Stratum 2=LDA: 2.6&lt;=DAS28-ESR&lt;3.2).</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-8.60</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-13.85</ci_lower_limit>
            <ci_upper_limit>-3.34</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Pain VAS: Week 44</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <method_desc>Stratified by geographic region and disease status at randomization (Stratum 1=Remission: DAS28-ESR&lt;2.6 or Stratum 2=LDA: 2.6&lt;=DAS28-ESR&lt;3.2).</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-9.49</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-14.72</ci_lower_limit>
            <ci_upper_limit>-4.26</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Pain VAS: Week 52</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <method_desc>Stratified by geographic region and disease status at randomization (Stratum 1=Remission: DAS28-ESR&lt;2.6 or Stratum 2=LDA: 2.6&lt;=DAS28-ESR&lt;3.2).</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-9.29</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-14.60</ci_lower_limit>
            <ci_upper_limit>-3.99</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in CRP and ESR at Each Visit During Period 1</title>
        <description>The DAS assessment is a derived measurement with differential weight given to each component. The DAS28-ESR and DAS28-CRP was calculated at every visit within the clinical database in period 1. The components of the DAS28 ESR score assessment are: Tender/ Painful Joint Count (28), Swollen Joint Count (28); ESR, Subject General Health VAS assessment. The components of the DAS28 CRP score assessment were: Tender/Painful Joint Count (28); Swollen Joint Count (28), hsCRP, and the Subject General Health VAS assessment. This efficacy measurement was made at every study visit.</description>
        <time_frame>Baseline, Weeks 4, 8, 16 and 24</time_frame>
        <population>The FAS for Period 1 (Open Label FAS) included all randomized participants who had at least one dose of open label study drug during Period 1 (ie, ETN or MTX).</population>
        <group_list>
          <group group_id="O1">
            <title>Open-Label Treatment</title>
            <description>Participants in open-label treatment received ETN 50 mg QW with MTX (with or without other DMARDs).</description>
          </group>
        </group_list>
        <measure>
          <title>Change in CRP and ESR at Each Visit During Period 1</title>
          <description>The DAS assessment is a derived measurement with differential weight given to each component. The DAS28-ESR and DAS28-CRP was calculated at every visit within the clinical database in period 1. The components of the DAS28 ESR score assessment are: Tender/ Painful Joint Count (28), Swollen Joint Count (28); ESR, Subject General Health VAS assessment. The components of the DAS28 CRP score assessment were: Tender/Painful Joint Count (28); Swollen Joint Count (28), hsCRP, and the Subject General Health VAS assessment. This efficacy measurement was made at every study visit.</description>
          <population>The FAS for Period 1 (Open Label FAS) included all randomized participants who had at least one dose of open label study drug during Period 1 (ie, ETN or MTX).</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="478"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>CRP: Week 4 (N= 465)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-14.07" spread="25.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CRP: Week 8 (N= 471)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-14.43" spread="23.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CRP: Week 16 (N= 472)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-14.71" spread="27.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CRP: Week 24 (N= 472)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-14.51" spread="27.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ESR: Week 4 (N= 473)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-17.32" spread="19.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ESR: Week 8 (N= 473)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-19.28" spread="21.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ESR: Week 16 (N= 473)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-21.10" spread="24.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ESR: Week 24 (N= 473)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-26.77" spread="26.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in CRP and ESR at Each Visit During Period 2</title>
        <description>The DAS assessment is a derived measurement with differential weight given to each component. The DAS28-ESR and DAS28-CRP was calculated at every visit within the clinical database in period 1. The components of the DAS28 ESR score assessment are: Tender/ Painful Joint Count (28), Swollen Joint Count (28); ESR, Subject General Health VAS assessment. The components of the DAS28 CRP score assessment were: Tender/Painful Joint Count (28); Swollen Joint Count (28), hsCRP, and the Subject General Health VAS assessment. This efficacy measurement was made at every study visit.</description>
        <time_frame>Baseline, Weeks 24, 28, 36, 44 and 52</time_frame>
        <population>The FAS included all randomized participants who met the period 2 DAS28-ESR inclusion criteria, had at least one dose of study drug during Period 2 (ie, ETN, MTX or PBO) and had at least one valid efficacy (DAS28-ESR) evaluation after randomization.</population>
        <group_list>
          <group group_id="O1">
            <title>Etanercept</title>
            <description>Participants were randomized to receive ETN 50 mg QW with MTX (with or without other DMARDs).</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants were randomized to receive PBO 50 mg QW + MTX (with or without DMARDs).</description>
          </group>
        </group_list>
        <measure>
          <title>Change in CRP and ESR at Each Visit During Period 2</title>
          <description>The DAS assessment is a derived measurement with differential weight given to each component. The DAS28-ESR and DAS28-CRP was calculated at every visit within the clinical database in period 1. The components of the DAS28 ESR score assessment are: Tender/ Painful Joint Count (28), Swollen Joint Count (28); ESR, Subject General Health VAS assessment. The components of the DAS28 CRP score assessment were: Tender/Painful Joint Count (28); Swollen Joint Count (28), hsCRP, and the Subject General Health VAS assessment. This efficacy measurement was made at every study visit.</description>
          <population>The FAS included all randomized participants who met the period 2 DAS28-ESR inclusion criteria, had at least one dose of study drug during Period 2 (ie, ETN, MTX or PBO) and had at least one valid efficacy (DAS28-ESR) evaluation after randomization.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="163"/>
                <count group_id="O2" value="168"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>CRP: Week 24 (N= 161, 168)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-16.92" spread="28.64"/>
                    <measurement group_id="O2" value="-14.47" spread="21.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CRP: Week 28 (N= 160, 166)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-15.94" spread="28.52"/>
                    <measurement group_id="O2" value="-8.59" spread="25.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CRP: Week 36 (N= 162, 167)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-15.56" spread="31.36"/>
                    <measurement group_id="O2" value="-7.45" spread="25.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CRP: Week 44 (N= 162, 167)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-16.47" spread="30.09"/>
                    <measurement group_id="O2" value="-6.72" spread="26.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CRP: Week 52 (N= 162, 167)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-16.29" spread="30.74"/>
                    <measurement group_id="O2" value="-7.07" spread="26.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ESR: Week 24 (N= 163, 168)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-31.52" spread="22.55"/>
                    <measurement group_id="O2" value="-31.02" spread="24.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ESR: Week 28 (N= 163, 168)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-26.96" spread="23.04"/>
                    <measurement group_id="O2" value="-20.28" spread="23.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ESR: Week 36 (N= 163, 168)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-26.10" spread="24.17"/>
                    <measurement group_id="O2" value="-16.94" spread="23.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ESR: Week 44 (N= 163, 168)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-24.39" spread="22.99"/>
                    <measurement group_id="O2" value="-16.14" spread="23.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ESR: Week 52 (N= 163, 168)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-23.56" spread="21.88"/>
                    <measurement group_id="O2" value="-16.27" spread="22.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>CRP: Week 28</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.014</p_value>
            <method>ANCOVA</method>
            <method_desc>Stratified by geographic region and disease status at randomization (Stratum 1=Remission: DAS28-ESR&lt;2.6 or Stratum 2=LDA: 2.6&lt;=DAS28-ESR&lt;3.2).</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-5.22</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-9.39</ci_lower_limit>
            <ci_upper_limit>-1.05</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>CRP: Week 36</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.011</p_value>
            <method>ANCOVA</method>
            <method_desc>Stratified by geographic region and disease status at randomization (Stratum 1=Remission: DAS28-ESR&lt;2.6 or Stratum 2=LDA: 2.6&lt;=DAS28-ESR&lt;3.2).</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-6.27</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-11.09</ci_lower_limit>
            <ci_upper_limit>-1.46</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>CRP: Week 44</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <method_desc>Stratified by geographic region and disease status at randomization (Stratum 1=Remission: DAS28-ESR&lt;2.6 or Stratum 2=LDA: 2.6&lt;=DAS28-ESR&lt;3.2).</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-7.75</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-12.06</ci_lower_limit>
            <ci_upper_limit>-3.44</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>CRP: Week 52</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.001</p_value>
            <method>ANCOVA</method>
            <method_desc>Stratified by geographic region and disease status at randomization (Stratum 1=Remission: DAS28-ESR&lt;2.6 or Stratum 2=LDA: 2.6&lt;=DAS28-ESR&lt;3.2).</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-7.16</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-11.48</ci_lower_limit>
            <ci_upper_limit>-2.85</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>ESR: Week 28</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <method_desc>Stratified by geographic region and disease status at randomization (Stratum 1=Remission: DAS28-ESR&lt;2.6 or Stratum 2=LDA: 2.6&lt;=DAS28-ESR&lt;3.2).</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-5.86</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-9.23</ci_lower_limit>
            <ci_upper_limit>-2.49</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>ESR: Week 36</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <method_desc>Stratified by geographic region and disease status at randomization (Stratum 1=Remission: DAS28-ESR&lt;2.6 or Stratum 2=LDA: 2.6&lt;=DAS28-ESR&lt;3.2).</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-8.69</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-12.33</ci_lower_limit>
            <ci_upper_limit>-5.05</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>ESR: Week 44</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <method_desc>Stratified by geographic region and disease status at randomization (Stratum 1=Remission: DAS28-ESR&lt;2.6 or Stratum 2=LDA: 2.6&lt;=DAS28-ESR&lt;3.2).</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-7.59</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-11.38</ci_lower_limit>
            <ci_upper_limit>-3.80</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>ESR: Week 52</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <method_desc>Stratified by geographic region and disease status at randomization (Stratum 1=Remission: DAS28-ESR&lt;2.6 or Stratum 2=LDA: 2.6&lt;=DAS28-ESR&lt;3.2).</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-6.32</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-10.03</ci_lower_limit>
            <ci_upper_limit>-2.60</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were reported from the signing of the informed consent to 28 days after the last dose of study medication through the last participant's visit.</time_frame>
      <desc>The Open Label Safety Population is defined as all participants who had at least one dose of open label study drug during Period 1. The Double Blind Safety Population is defined as all randomized participants who had at least one dose of study drug during period 2.</desc>
      <group_list>
        <group group_id="E1">
          <title>Open-Label Treatment</title>
          <description>Participants in open-label treatment received ETN 50 mg with MTX (with or without other DMARDs).</description>
        </group>
        <group group_id="E2">
          <title>Etanercept</title>
          <description>Participants were randomized to receive ETN 50 mg QW with MTX (with or without other DMARDs).</description>
        </group>
        <group group_id="E3">
          <title>Placebo</title>
          <description>Participants were randomized to receive PBO 50 mg QW + MTX (with or without DMARDs).</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 18.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="489"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="176"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="489"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="489"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="176"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="489"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="176"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Sudden death</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="489"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="176"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Drug-induced liver injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="489"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="176"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="489"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="489"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="489"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Extradural abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="489"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="489"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="489"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Intervertebral discitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="489"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="489"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Pyelonephritis acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="489"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Salmonella sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="489"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="176"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Femoral neck fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="489"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="489"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Ulna fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="489"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="176"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="489"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Rheumatoid arthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="489"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Myopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="489"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="176"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 18.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="489"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="176"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="28" subjects_affected="26" subjects_at_risk="489"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="167"/>
                <counts group_id="E3" events="9" subjects_affected="9" subjects_at_risk="176"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Pfizer ClinicalTrials.gov Call Center</name_or_title>
      <organization>Pfizer, Inc.</organization>
      <phone>1-800-718-1021</phone>
      <email>ClinicalTrials.gov_Inquiries@pfizer.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

